POPULARITY
35 episodes with bmtcn
3 episodes with bmtcn
3 episodes with bmtcn
3 episodes with bmtcn
3 episodes with bmtcn
3 episodes with bmtcn
3 episodes with bmtcn
“[My mom] would always be very inspirational whenever I would see her studying so long. And when she finally got to be a nurse, I always admired her vocation and compassion with her patients. She would always go above and beyond for all of her patients. I also got inspired a lot by my brother, as well, just seeing how passionate he was for caring for his patients for the families as well, and helping them deal with the any grief or loss that they were experiencing, Carolina Rios, MSN, RN, CPhT, told Valerie Burger, RN, MA, MS, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about families in nursing. Burger spoke with Carolina, her mother Lissette Gomez-Rios, MSN, APRN, AGACNP-BC, FNP-BC, OCN®, BMTCN®, and her brother Carlos Rios, BSN, RN, BMTCN®, about how having multiple nurses in their family has affected them personally and professionally. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 327: Journey of a Student Nurse: Choosing Oncology Nursing and the Value of a Professional Home ONS Voice articles: Innovation Inspires Hope: A Nurse's Journey of Passion and Purpose When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places Is Work–Life Balance Possible? The Evidence Says It Isn't—Rather, It's About Reframing Our Thinking ONS Nurse Well-Being Learning Library Oncology Nursing Foundation Resiliency Resources Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Lissette: “Being in the oncology nursing as a family, when I feel the necessity to talk to them, they listen to me. They pay attention, and we help each other to cope, especially when there is a loss of our patients, so we help each other. We are understanding. We give them compassion and the advice that we need.” TS 6:51 Carlos: I remember growing up—and [my mom] would always be in school and in the healthcare field, so I knew growing up I wanted to be in the healthcare field. She was the one that guided me into going to nursing because at a certain point, I wasn't sure what I was going to be doing. She guided me, and once I started doing nursing, this has been the career I want to do, I want to continue doing. I'm very grateful for her guiding me into nursing.” TS 9:48 Carolina: “Anytime I had a question I would ask them. They would always help me out, make sure I really understood. It would actually be a little funny because sometimes they would overexplain, and I was a little overwhelmed, and I would have to be like, ‘OK, let's dial it back. Let's get back to the basics.'” TS 14:22
“Now, what we found is that epigenetics is actually heritable and it's actually reversible. And we can now manipulate these principles with pharmacotherapy drugs,” Eric Zack, RN, OCN®, BMTCN®, clinical assistant professor at Loyola College Chicago Marcella Niehoff School of Nursing in Chicago, IL, and RN3 at Rush University Medical Center in Chicago, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the epigenetics drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours (including 40 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 28, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the epigenetics drug class. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ Pharmacology 101 series ONS Voice articles: Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Oncology Drug Reference Sheets What Is MCED Testing? ONS book: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition) ONS Biomarker Database ONS course: Genomic Foundations for Precision Oncology ONS Huddle Card: Financial Toxicity ONS Learning Libraries: Genomics and Precision Oncology Oral Anticancer Medication American Cancer Society: Patient Programs and Services Centers for Disease Control and Prevention: Epigenetics, Health, and Disease Leukemia & Lymphoma Society: Financial Support National Institutes of Health: Epigenetics University of Pennsylvania: Epigenetics Institute University of Utah: Genetic Science Learning Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Epigenetics is influenced by several factors. Right now, there's about seven of them that we've identified, and we can only manipulate right now about two of those seven. So the first one is DNA methylation. When you methylate DNA, that's adding or subtracting a methyl group, which is CH3, chemically. The addition of methyl to DNA tightens the DNA around the chromatin, which then can block some genes from being expressed.” TS 7:21 “Histones basically package DNA into the chromatin, which is a mixture of DNA and proteins, and they spool around this structure like the DNA is coiled around that. And again, it has to do with how tight or loose that is coiled. That determines if the genes are expressed or not. And again, we found that histones also play a role in DNA repair as well as regulating the cell cycle.” TS 8:21 “When we're dealing with the azacitidine and decitabine, these drugs cause pancytopenia. Pancytopenia is neutropenia, thrombocytopenia, and anemia. So it affects the complete blood count. We see GI toxicity, nausea, vomiting, diarrhea, constipation, sometimes mouth sores, and urticaria—hives.” TS 15:34 “It's really, really important to take these drugs exactly as they are prescribed. They have to follow the doctor's orders carefully, which requires taking them properly, doing the proper follow up. There's a lot of blood tests and appointments that we have to do to make sure that everything is okay. And again, because we know when there is nonadherence, the disease progresses and becomes resistant, so that's a really, really important teaching point. We have to monitor the patient for expected side effects and unexpected side effects.” TS 23:58 “Now, we expect the landscape to change dramatically over the next few years. And again, it's just an explosion of science information. As we learn more about the science, it's going to translate into practice. We're always identifying new biomarkers. These biomarkers are essentially DNA mutations or variations. There's so many variants of unknown significance.” TS 30:02 “Every patient deserves biomarker testing. Very important, whether it's through IHC, polymerase chain reactions, or the most common next-gen sequencing. Again, there's several companies out there that have standard kits available.” TS 31:33 “This is a precision medicine. This is what we've always dreamed about—tailoring the treatment to the specific patient. We've gone away from treating standard diseases, like lung cancer and breast cancer, the way they're supposed to be treated to now looking at these biomarkers and using epigenetic drugs and other medications tailored to those variants that that patient is having, not necessarily based on their disease type.” TS 33:59
“Don't be afraid of applying, even if you've never planned a conference before, and you think, ‘Well, I have no idea what I'm doing.' You probably know more than you think you do. You probably have more connections than you think you do, and it is such a worthwhile experience,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, conferences oncology clinical specialist at ONS, during a conversation about serving on a planning committee for an ONS conference. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Episode Notes Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD contact hours. Oncology Nursing Podcast™ episodes: Episode 323: What It's Like to Participate in an ONS Think Tank Episode 320: What It's Like to Be a Peer Reviewer or Associate Editor for an ONS Journal Episode 309: What Brings You to ONS Congress®? Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources ONS Voice articles: What Brings You Value in ONS? You Can Thank a Volunteer for That The Power of Connection in Oncology Nursing What Brings You Value in ONS? You Can Thank a Volunteer for That The Power of Connection in Oncology Nursing Clinical Journal of Oncology Nursing article: What Is It Like to Chair the ONS Bridge™ Content Planning Team? ONS Volunteer Opportunities ONS Congress ONS Evidence-Based Practice Learning Library To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “I saw a link on the ONS website looking for volunteer opportunities and applied, not thinking that I'd actually get chosen because I had never done anything like this before. I had spoken at conferences, but I had never been part of the planning committee. The application [had] some open-ended questions about what your expertise is and where your interests lie. … And then I got a phone call from the planning chair for that year, and we talked a little bit more in depth about the questions that were on the application, and my interests, and how I thought I would fit on the team.” TS 2:05 “The main part [of the work] was topic selection and then speaker selection once we narrowed down the topics. I feel like there was a lot of brainstorming and group effort to both of those things. You don't have to individually have an exact topic or an exact speaker. There was a lot of ‘I think this general broad topic would be good,' and then we narrowed it down as a group to something that would fit into a 45-minute presentation.” TS 4:30 “We talked about interventional radiology and how it seemed like it was taking on much more of a bigger role in oncology and how that could fit into the conference and whether we wanted to have a specific topic or an overview of the things that interventional radiology can offer for oncology patients. And we ended up doing kind of like a 101 topic on that one, because it was a newer topic that people were kind of interested in just hearing, like, ‘Hey, what do you guys do for cancer patients?'” TS 8:44 “I learned a lot about the backstage process of conferences. I had spoken before, but seeing the other side of it was a whole different picture—and all the work that goes into it—and I really learned a lot about picking the topics and how do we find the best information and the best sort of new themes to present to every time.” TS 12:04 “Just do it. Don't be afraid of applying, even if you've never planned a conference before, and you think, ‘Well, I have no idea what I'm doing.' You probably know more than you think you do. You probably have more connections than you think you do, and it is such a worthwhile experience. And you learn so much about yourself and about the other people on the team. And the information that you're presenting just is huge for a lot of people. So if you're even thinking about it, just fill out the application.” TS 14:06
“Under normal conditions, EGFR [epidermal growth factor receptor] is in an auto-inhibited state. And it's only when it's needed that it's upregulated. But when you have cancers that there is either a mutation in the EGFR or an overexpression, what you see is a dysregulation of normal cellular processes. So you get overexpression or switching on of prosurvival or antiapoptotic responses,” Rowena “Moe” Schwartz, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the EGFR inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to EGFR inhibitor drugs. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Pharmacology 101 series Episode 250: Cancer Symptom Management Basics: Dermatologic Complications Episode 226: Patient Education for Next-Generation Sequencing to Guide Cancer Therapy Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Management Strategies for Cutaneous Toxicity From EGFR Inhibitors Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Osimertinib Oncology Drug Reference Sheet: Panitumumab Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition) ONS courses: ONS Cancer Biology™ ONS/ONCC Chemotherapy Immunotherapy Certificate™ Safe Handling Basics Clinical Journal of Oncology Nursing articles: Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices Medication Adherence Barriers: Development and Retrospective Pilot Test of an Evidence-Based Screening Instrument ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity Nursing Management of Skin Toxicities in Diverse Skin Tones ONS Bispecific Antibody Video ONS Learning Libraries: Genomics and Precision Oncology Oral Anticancer Medication Oral Chemotherapy Education Sheets Seminars in Cancer Biology article: EGFR signaling pathway as therapeutic target in human cancers To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “It wasn't until 2004 that the mutations affecting the tyrosine kinase domain of epidermal growth factor receptor was linked to the responses that were seen in gefitinib. And that's when we really started to understand the way that this was targeting certain patients' cancers. So that led to the phase three study. People may remember the IPASS study that demonstrated that when patients had an activating mutation of EGFR, that that was a really good biomarker that selected out patients that would respond to therapy.” TS 2:58 “The new player on the market is the bispecific. … This was a bispecific that was developed to hit two different targets. The one target is EGFR. The second target was MET. And the reason MET was targeted is because when you have patients who are on EGFR tyrosine kinase inhibitors, they do so well. But over time, resistance develops. And one of the mechanisms that are thought to be important for resistance is that MET pathway. So it was a development of a bispecific antibody that hit two different targets, EGFR and MET, hoping that you would get less resistance.” TS 7:12 “The other thing that I see with these agents is seeing them combined with chemotherapy. For a long time, it was these drugs were used as the single approach to someone with non-small cell lung cancer who had an EGFR mutation, and they did well. But I think we're starting to see that because resistance does develop, that there may be roles for combination with chemotherapy, and you're seeing that in terms of drug approval.” TS 19:10 “I think that people that don't work in the clinic, say, with non-small cell lung cancer—they think of these as a group and don't realize the uniqueness of specific agents, what mutations that they hit that affected those that penetrate into the [central nervous system], the drug interactions that are specific for certain agents. So I think that's one of the common misconceptions.” TS 22:02 “The education, because it evolves so rapidly, is to realize that what you know, if it's from a year ago, may not be the full picture. And so again, I'm going to call out ONS for the phenomenal resources on the Genomics and Precision Oncology Learning Library to help providers learn. And that is updated, and it is readily available. I think it is phenomenal, and I think it helps people build on their basic understanding of any of these types of therapy, including EGFR inhibitors.” TS 23:24
“Nurses really are the professionals who educate how to take these medicines, why we use multimodal therapies, why it isn't medicine alone—helping patients to understand that pain is a biopsychosocial spiritual phenomenon, and the pills are just going to hit one little aspect of that entire phenomenon,” Judy Paice, PhD, RN, director of the cancer pain program at Northwestern University Feinberg School of Medicine in Chicago, IL, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about nursing practices for cancer pain management. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 11, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to managing pain in patients with cancer. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Episode 165: Safely Administer and Prescribe Opioids for Cancer-Related Pain Episode 3: Opioids, Addiction, and Complex Care ONS Voice articles: Alternative Funding Programs: Don't Be Fooled by Promises of 'Free' Specialty Cancer Drugs CMS's Chronic Pain Experience Journey Map Will Help Patients and Providers Latest CDC Clinical Practice Guideline Facilitates Safe Use of Opioids for Pain What the Evidence Says About Tai Chi in Cancer Care ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) ONS courses: Essentials in Advanced Practice Symptom Management Treatment and Symptom Management—Oncology RN Clinical Journal of Oncology Nursing articles: Effects of a Nurse-Initiated Telephone Care Path for Pain Management in Patients With Head and Neck Cancer Receiving Radiation Therapy Pain Management Revisited Symptom Distress: Implementation of Palliative Care Guidelines to Improve Pain, Fatigue, and Anxiety in Patients With Advanced Cancer Oncology Nursing Forum articles: Barriers for Nurses Providing Cancer Pain Management: A Qualitative Systematic Review Framing Cancer Survivors' Access to and Use and Disposal of Prescribed Opioids Within the Opioid Epidemic Interventions for Managing a Symptom Cluster of Pain, Fatigue, and Sleep Disturbances During Cancer Survivorship: A Systematic Review ONS Position Statement: Cancer Pain Management ONS Learning Library: Pain Management Diagnostics article: Diagnosing Pain in Individuals With Intellectual and Developmental Disabilities: Current State and Novel Technological Solutions End-of-Life Nursing Education Consortium Harvard Implicit Association Test National Cancer Institute's Cancer Pain PDQ Health professional version Patient version Opioid Risk Tool Pain Medicine article: A Tactile Pain Evaluation Scale for Persons With Visual Deficiencies To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Who do patients speak to about their pain? They're often afraid to tell their oncologist, and studies have backed this up. The patient is worried that if they admit to more symptoms, they won't be able to enroll in that clinical trial, so they talk to us, the nurse. And part of our role is to encourage that dialog and assess the pain fully.” TS 7:00 “The nonpharmacologic, which is equally important—and I see these as partners in relief, not as one versus the other. But we may have physical measures like [physical therapy] and [occupational therapy] and orthotics, heat and cold. We may have more emotional or psychological kinds of therapies—cognitive behavioral techniques. We may have integrative measures—mindfulness guided imagery, yoga, tai chi. And some of these kind of transcend multiple categories.” TS 15:57 “For breakthrough [pain], we try to again treat the underlying cause. If this is an unstable vertebral body, is a kyphoplasty or vertebroplasty a possibility for this patient? If there's compression of nerve roots, might an epidural steroid injection or some other interventional procedure help, so that when the patient stands—and that's often what we see the breakthrough pain occurring—or moves position, maybe we can provide some relief that's more directed to the site of pain or source.” TS 24:35 “I set expectations. Again, this is where nurses are key. It is so important that you use these medicines for pain. Yes, they're going to make you feel a little bit less anxious, a little warm and fuzzy, and maybe even help you fall asleep at night, but you cannot use them for that purpose. You can only use these medicines for pain control. We have other medicines to help you if you're feeling anxious or if you're having trouble sleeping at night. And if you use your opioids for those purposes, you are going to get into trouble.” TS 41:11
“The reality is that we are responsible for creating a culture of safety together for everybody in the clinical area. We have to think not only about ourselves and our personal risk, but how exposure to these hazardous drugs persists in the work environment for everybody. And we have to be part of the solution for everybody, even if it's not something that we're personally really worried about being exposed to,” AnnMarie Walton, PhD, MPH, RN, OCN®, CHES, FAAN, associate professor at Duke University School of Nursing in Durham, NC, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about updates to the fourth edition of Safe Handling of Hazardous Drugs, one of ONS's book publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 20, 2026. AnnMarie Walton serves in a compensated consultant role with Splashblocker LLC and as a compensated speaker for BD. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to safe handling of hazardous drugs. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast™ episodes: Episode 325: What Changed in the 2024 ASCO/ONS Antineoplastic Administration Safety Standards Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE Strategies to Promote Safe Medication Administration Practices ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS/ONCC Chemotherapy Immunotherapy Certificate™ Safe Handling Basics Clinical Journal of Oncology Nursing articles: Environmental Risk Factors: The Role of Oncology Nurses in Assessing and Reducing the Risk for Exposure Oral Chemotherapy: A Home Safety Educational Framework for Healthcare Providers, Patients, and Caregivers Oral Chemotherapy: An Evidence-Based Practice Change for Safe Handling of Patient Waste Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Oncology Nursing Forum articles: Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Randomized Controlled Trial of an Intervention to Improve Nurses' Hazardous Drug Handling ONS Learning Library: Safe Handling of Hazardous Drugs Joint ONS and Hematology/Oncology Pharmacy Association position statement: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs ONS Voice video: Hazardous Drug Surface Contamination—The Science Behind the Study To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “We know that this book is used in practice sites across the country and increasingly around the world, and we have the privilege of answering lots of questions of ONS's members routinely. And we've also been part of writing guidance documents for ONS. And so, we utilized, as well, some of those questions that have come to us, and we know what people want to know more about. So we've made sure that we've developed a book that would be the most helpful in clinical practice settings.” TS 2:42 “We ensured that the book was in alignment with all of the most recent organizational position statements, standards, and recommendations. And there have been some big ones between the publication of the third and fourth book. So USP 800 is one that everyone knows about, and that became enforceable in November of 2023. … The ONS/HOPA [Hematology/Oncology Pharmacy Association] position statement, which was most recently updated in 2022, was also folded into this book. NIOSH [National Institute for Occupational Safety and Health] came out with two new guidance documents in 2023, and I had the opportunity to serve as a reviewer on one and a contributor to the other. Those two NIOSH guidelines have been folded into this book And then the ONS Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice, which MiKaela Olsen was a lead editor on and I was an author for, have also been folded into this text.” TS 7:01 “We've understood the NIOSH hierarchy of controls for years, and if we look at that hierarchy, it tells us that PPE is important but also the least effective when it comes to controlling exposure. And what's slightly more effective is administrative controls, which are things like changes in our practices, more education, and training. And then even more powerful than administrative controls are engineering controls, and these are your closed-system transfer devices, for example, that are really important in minimizing exposure.” TS 10:31 “[Toilet pluming] is a place that I, for better or worse, spend a lot of time. And I have a colleague, Tom Connor from NIH [National Institutes of Health], who likes to joke when people ask him about his work. He says, ‘Oh, it's in the toilet.' And so I'm going to steal that from him and say a lot of my research is in the toilet, too.” TS 13:16 “I feel like people don't know how contaminated toilets are and how contaminated floors are. And I've already told you my tip about leaving your work shoes outside. But I think if people were more aware that the toilets and the floors are often the most contaminated places on a unit, there would be more attention paid to people who are coming into contact with those surfaces and bear a lot of the exposure risk.” TS 22:51
“Transfusion safety is really a registered nurse activity, and I just continue to reiterate the blessing of nursing assessment, getting those vitals before the transfusion, and then monitoring them closely and stopping the transfusion if they have a reaction, because that's really an assessment, and we can't delegate that to nonlicensed staff. And so that's really why we just celebrate that nurses have such a great role in transfusion safety,” Renee LeBlanc, BSN, RN, manager of the infusion services office at Fred Hutchinson Cancer Center in Seattle, WA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about administration of plasma and cryoprecipitate. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by May 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to plasma and cryoprecipitate administration. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 234: Oncologic Emergencies 101: Thrombotic Thrombocytopenia Purpura Episode 228: Oncologic Emergencies 101: Disseminated Intravascular Coagulation Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: Nursing Considerations for Adverse Events From CAR T-Cell Therapy Manage Thrombosis in Patients With Cancer ONS courses: Essentials in Oncologic Emergencies for the Advanced Practice Provider Oncologic Emergencies ONS book: Understanding and Managing Oncologic Emergencies: A Resource for Nurses (third edition) Clinical Journal of Oncology Nursing article: STAT: Cytokine Release Syndrome ONS Huddle Cards Cytokine Release Syndrome Disseminated Intravascular Coagulation AABB (Association for the Advancement of Blood and Biotherapies, formerly American Association of Blood Banks) American Association of Clinical Oncology Blood Bank Guy (Joe Chaffin, MD) Joint Commission: Patient Blood Management Certification Review Process Guide 2021 To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Plasma is indicated for massive transfusions and emergent reversal of warfarin therapy–related intracranial hemorrhage. Nurses may also see plasma ordered pre-op for multiple coagulation deficiencies or factor XI deficiency.” TS 2:58 “Surgical centers performing procedures with large-volume blood loss would be a prime location for staff to be experts in transfusing plasma and cryo. Nurses caring for patients with cytokine release syndrome may be familiar with monitoring for hypofibrinogenemia. Cryoprecipitate in this setting may be given more prophylactically than for a patient who's actively bleeding or having a procedure.” TS 6:48 “Plasma coagulation factors have a short half-life. Transfusing as close to the procedure will ensure the highest level of factor activity at the time of the procedure. Nurses can ensure best outcomes through care coordination and timing the transfusions as close to the procedure as possible. So we don't want to start transfusing plasma at midnight if the factors are going to be expiring and their procedure isn't until 9:00 in the morning.” TS 10:40 “One of the questions that I get sometimes, especially with plasma, is, ‘I don't have time to be at the bedside for 15 minutes for four units.' Remember that each unit is a different donor, and what they eat, what kind of antibodies they have, whether they were pregnant—it's all part of that experience. It's not the same plasma product given four different times or three different times. And so just really drawing nurses into the value of being at the bedside for that first 15 minutes of that final determination of acceptability and tolerance.” TS 14:20
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.
During the 2024 Oncology Nursing Society Congress, CancerNetwork® spoke with multiple registered nurses about research they presented on safely administering treatment options such as CAR T-cell therapy and bispecific T-cell engager (BiTE) therapy in patients with multiple myeloma and other malignancies. Ishmael Applewhite, BSN, RN-BC, OCN, a registered nurse at the University of Rochester Medical Center, highlighted the management of adverse effects including peripheral neuropathy in patients with multiple myeloma undergoing treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti). He discussed these treatment strategies in the context of a presentation he gave on findings from the phase 3 CARDITUDE-4 trial (NCT04181827), in which investigators assessed treatment with cilta-cel in those who were refractory to lenalidomide (Revlimid).1 According to Applewhite, cilta-cel may offer “another path” aside from standard treatment options such as chemotherapy and give “more time” to patients with multiple myeloma. Additionally, Leslie Bennett, MSN, RN, a nurse coordinator at Stanford Healthcare, highlighted the importance of identifying and mitigating cranial nerve palsy (CNP) in patients with multiple myeloma who are treated with cilta-cel. At the conference, Bennett presented data on CNP outcomes across various studies, which included the phase 1/2 CARTITUDE-1 trial (NCT03548207), phase 2 CARTITUDE-2 trial (NCT04133636), and phase 3 CARTITUDE-4 trial (NCT04181827).2 According to findings from this presentation, patients had CNP onset at a median of approximately 3 weeks after beginning treatment with cilta-cel. Most cases of CNP tended to occur in male patients. Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®,clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, spoke about a study designed to evaluate the feasibility and safety of using BiTE therapy to treat those with cancer in an outpatient setting.3 Mooney emphasized multidisciplinary collaboration among nurses, pharmacy providers, and social workers as part of monitoring patients for toxicity as they undergo treatment with BiTE agents. References 1. Applewhite I, Elfrink G, Esselmann J, Lonardi C, Florendo E, Sidiqi MH. Efficacy and adverse events after ciltacabtagene autoleucel treatment in the CARTITUDE-4 as-treated population consisting of patients with lenalidomide-refractory multiple myeloma who received 1-3 prior lines of therapy. Presented at: 2024 Oncology Nursing Society Congress; April 24-28, 2024; Washington, DC. 2. Bennett L, Kruyswijk S, Sidana S, et al. Incidence and management of cranial nerve impairments in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Presented at: 2024 Oncology Nursing Society Congress; April 24-28, 2024; Washington, DC. 3. Mooney K, Allen N, Anderson K, Zukas A. Taking a BiTE out of hospital admission days using a team approach to managing patients at risk for treatment related toxicities. Presented at: 2024 Oncology Nursing Society Congress; April 24-28, 2024; Washington, DC.
“It was really the ability to be able to connect with many individuals from my profession. Reflecting on what initially drew me to ONS Congress, I can't help but reminisce about my first time attending in 2002. I was going down memory lane the other day and found some pictures from my first time attending. As I reflected, I could not help but feel immensely grateful for the support and education I received as a novice nurse during that time from attending Congress,” Jessica MacIntyre, DNP, MBA, APRN, AOCNP®, 2024–2026 ONS president, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about ONS Congress. Taylor spoke with several 2024 ONS Congress attendees, asking the question “What brought you to ONS Congress?” Listen to their stories and learn how the conference has affected their careers in this special episode. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes Information on submitting an abstract to ONS Congress Oncology Nursing Foundation ONS Congress Scholarships Oncology Nursing Podcast episodes: Episode 258: ONS Through the Ages: Stories From the Early Days With Cindi Cantril and George Hill Episode 160: Build Innovative Staff Education Tools and Resources Episode 191: Explore Orientation Opportunities for New-to-Practice Nurses ONS Voice articles: Our Unified Voices Can Improve Cancer Survivorship Care Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies ONS Congress presentations from episode guests The Nurse as an Effective Educator: Facilitating Patient-Centered Learning (Beau Amaya) Powerful Outcomes From Nurse and Patient Policy Advocacy (Gilanie De Castro) Back to Basics: Utilizing Huddles to Emphasize Standard Care and Maintenance of Central Venous Catheters in an Effort to Reduce CLABSI (Erin Hillmon) Enhancing Triage Precision: Nurse Navigation's Impact on a Lymphedema Program (Jessica MacIntyre) Implementing a Graduate Nurse Residency Program (Leah Scaramuzzo) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “What I want to accomplish is really to contribute significantly to an organization that has contributed so greatly to me. And until you go to Congress, you don't fully realize the ripple effect that ONS has on the field of oncology nursing. They really are a cornerstone to our profession. So when I volunteer with ONS, I feel like I'm serving the oncology nursing community as a whole, and I'm so grateful to get to do that on a national level.” (Stacey Clements, BSN, RN) TS 3:35 “What is bringing me to Congress is to talk about patient education, health literacy, ways that we can improve the patient experience and help them understanding. And I think this is such an important topic because it's what we do at the core of nursing. We really teach patients and their caregivers how to take care of themselves. And sometimes we forget that it's not just a checklist to get the education done. It's really learning what the patient needs, what they need to think about—some consideration about what may be affecting the way that they're retaining information. Then hopefully I can give some tools and have some discussion with many different nurses across the U.S.” (Beau Amaya, MS, RN, OCN®) TS 5:04 “Why I am so excited to attend Congress is that it really gives us an opportunity to work together with our colleagues, learn what each other is doing, and kind of leverage our collective wisdom. So this way we work smarter instead of harder.” (Leah Scaramuzzo, MSN, RN, MEDSURG-BC, AOCN®) TS 7:58 “I was a scholarship recipient, which I was super excited to receive this year for the Congress 2024 in D.C. … Out of COVID, we all were virtual, so I wanted to able to see people in person and attend a national event. Also, I'm looking forward to reigniting my passion for oncology nursing because you kind of get burned out after a while in this field.” (Brenda Marsolek, BSN, RN, OCN®) TS 9:14 “I'm also really excited to share my role as a nurse resident. I hear a lot that new nurses shouldn't be hired in oncology or it's difficult to hire them. And I did it. I successfully did it with the help of [Leah and Brenda]. And so, I think other people can do that as well and that we can have new grad nurses have really healthy careers in oncology in the future.” (Brandy Thornberry, ASN, RN, OCN®) TS 10:38 “I chose to be a presenter this year because I always enjoyed listening to the presentations that everyone else brings to Congress. I always learned so much. I wanted the opportunity to be able to share one of the projects I did last year that had great results attached to it, so that hopefully others can listen to my presentation and maybe take something away from it back to their own centers.” (Erin Hillmon, MSN, RN, BMTCN®) TS 11:28 “Nurses can find ways to engage in shaping health policy. Many nurses don't recognize the connection between health policy and the bedside. Policies beyond one's institutions or organizations have a direct impact on how we nurses practice. And my goal is to empower nurses to understand that because of our professional experience, education, and interactions with those populations who we care for, we are really poised to influence and shape health policy.” (Gilanie De Castro, MSN, RN, OCN®, NE-BC, CNML) TS 14:38 “The big thing I want to let everybody know about Congress is that there's so much to learn, and there's so much experience that every attendee brings. No matter what level of education you have, what setting you work in, what kind of patients you take care of, everybody has something that they can bring to the table. It doesn't matter where you learn this information either. There's lots of sessions, posters, and networking roundtables. What I've learned in these few years is really just embracing what Congress can bring to everybody. So for anybody that's on the fence, I'd urge you to take that leap and register. Attending Congress is a decision you won't regret.” (Holly Tenaglia, DNP, APRN, AGCNS-BC, OCN®) TS 19:47
“One of the things that I know Dr. [Tom] Connor worked on very heavily in his career is the long-term impact on the health of nurses and other exposed healthcare workers. We definitely need more longitudinal studies, which are difficult to do. And it's not something that you see every day where I talk to chemo nurses and said, ‘Hey, I've been in this 20 years. It hasn't bothered me at all.' Well, until it does. Therefore, it's so important when we're training incoming nurses—how very important it is to start with these practices early in the career and throughout the career,” Charlotte A. Smith, RPh, MS, senior regulatory advisor at Waste Management PharmEcology Services in Milwaukee, WI, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about hazardous drug and waste disposal. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to hazardous drugs and hazardous waste. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 209: Updates in Chemo PPE and Safe Handling Episode 142: The How-To of Home Infusions ONS Voice articles: Two Oncology Nurses Implement Process to Allow Patients to Disconnect Pumps From the Comfort of Their Own Homes The Oncology Nurse's Role in Oral Anticancer Therapies Strategies to Promote Safe Medication Administration Practices ONS Safe Handling of Hazardous Drugs Learning Library ONS position statement: Infusion of Antineoplastic Therapies in the Home ONS book: Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Environmental Risk Factors: The Role of Oncology Nurses in Assessing and Reducing the Risk for Exposure Oral Chemotherapy: A Home Safety Educational Framework for Healthcare Providers, Patients, and Caregivers Oral Chemotherapy: An Evidence-Based Practice Change for Safe Handling of Patient Waste Reconciliation and Disposal of Oral Medication: Creating a Safe Process for Clinical Research Personnel Pharmacy Practice News article: Applying NIOSH Hazardous Drug Assessment of Risk Principles To Home Healthcare (by Charlotte Smith and Tom Connor) Books mentioned in this episode: Silent Spring by Rachel Carson Our Stolen Future by Theo Colborn, Diane Dumanoski, and John Peterson Myers Generations at Risk by Ted Schettler, Gina Solomon, Maria Valenti, and Annette Huddle Drug Enforcement Agency: National Prescription Drug Takeback Day Environmental Protection Agency: Final Rule: Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine MD Anderson Cancer Center: Chemotherapy at Home: 9 Things to Know (patient resource) Memorial Sloan Kettering Cancer Center: Safe Handling of Chemotherapy and Biotherapy at Home (patient resource) National Institute for Occupational Safety and Health: Hazardous Drugs in Healthcare Settings Managing Hazardous Drug Exposures: Information for Healthcare Settings NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016 To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “A hazardous waste is a chemical, some of which are drugs, that EPA has determined is hazardous to the environment. Hazardous waste may be listed waste, which are given actual numbers, or they may be characteristic waste, which meets certain levels of concern, such as ignitability or toxicity. Only a small percentage of drug waste meets the EPA's definition of hazardous waste, including a number of chemotherapy drugs.” TS 2:09 “The poster child for hazardous waste is warfarin, which, as you may be aware, is not only appropriate for managing clotting time but is also available commercially as rat poison. This is an example of how chemicals can serve more than one purpose and why dosage and regulation are so important.” TS 4:04 “Some of your listeners may have been around long enough to remember the book Silent Spring, by Rachel Carson, in which she eloquently exposed the risks to many species by the widespread use of DDT, an insecticide, at that time. More recently, the book Our Stolen Future by Theo Colborn, a pharmacist, Diane Dumanoski, and John Peterson Myers, raised the specter of the effects of endocrine disruption on wildlife and humans. The effects of drugs like diethylstilbestrol, or DES, once given during pregnancy, on the fetus, impacted the risk of cancer and other untoward effects in the offspring. The book remains a dramatic reminder of the risk of exposure to hazardous chemicals, including drugs.” TS 9:37 “Providing a homecare checklist for both the nurse and the patient and family is a simple way to keep track of all areas that need to be covered. For example, who in the household may be at most risk from exposure? This list includes infants, elderly family members, caregivers, pregnant family members, even pets. Is there a secure area to store the drug that cannot be reached by children?” TS 14:21 “I think what happens—we become so into our routine that what we do on a daily basis, we just kind of go through and do it without always thinking about it. And we can forget that not everyone has the same context of understanding these risks that the medications have to both the environment and the individual exposed to them. And I know it's challenging to put on all the gowns and the gloves and whatnot. And, you know, it gets in the way of doing their job. It's important to educate each individual potentially exposed to these drugs, as if they do not have the understanding that we do. So embedding those consistent safety practices into daily routine is so imperative to ensure safe handling of hazardous drugs and then the proper disposal of hazardous waste pharmaceuticals.” TS 18:55
“When we're talking about the role of nurses in addressing these challenges, they play a critical role because of when they actually get to see patients. And so, if we can help with early identification and assessment, really finding out, using financial screening tools to identify any patients that might be at risk, early on, of financial toxicity, that can really allow for timely interventions,” Sarah Paul, LCSW, OSW-C, senior director of social work at CancerCare in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about financial toxicity in adolescent and young adult (AYA) cancer survivors. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 12, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to financial toxicity in the adolescent and young adult population. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 300: AYAs With Cancer: End-of-Life Care Planning Episode 294: AYAs With Cancer: Clinical Trial Enrollment Barriers and Facilitators Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 276: Support Young Families During a Parent's Cancer Journey Episode 62: Financial Toxicity Legislation ONS Voice articles: AYA Cancer Survivorship: Younger Survivors Face Different Challenges and Prefer More Casual Support Programs Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care How to Support Adolescents and Young Adults With Cancer at the End of Life LGB AYA Patients With Cancer Have High Burden of Chronic Conditions in Survivorship AYA Champions Clinic Fills Gaps in Care and Addresses Unmet Needs ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Clinical Journal of Oncology Nursing articles: Two Case Reports on Financial Toxicity and Healthcare Transitions in Adolescent and Young Adult Cancer Survivors Crucial Conversations: Addressing Informational Needs of Adolescents and Young Adults Diagnosed With Cancer A Nurse-Pharmacist Collaborative Approach to Reducing Financial Toxicity in Cancer Care Oncology Nursing Forum article: A Brief Screening Tool for Assessment of Financial Toxicity ONS Financial Toxicity Huddle Card ONS Nurse Navigation Learning Library Adolescent and Young Adult Cancer Awareness Week American Society of Clinical Oncology CancerCare Got Transition National Comprehensive Cancer Network Patient Advocate Foundation Triage Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “For nurses that are caring for AYA patients, it's really important to not only be aware of financial toxicity but know how to assess for financial toxicity because of the pivotal stage that these patients are at in their life. They often don't have the financial stability or insurance coverage that adults who are maybe middle age or even in the older adult population might have.” TS 2:11 “The idea of [AYAs] not really understanding insurance coverage—I think it's really important that as a team, we simplify some of this complex information, breaking it down into more manageable steps and providing that guidance on the documents and all the information that's needed to apply [for financial assistance].” TS 8:59 “We see significant impacts in the AYA community, especially those that are in school or at the early stages of their career, because putting a job or school on hold to focus on treatment can have long-term effects. So, we see a couple of things. In education, we see academic delays; interrupting education can delay graduation or achievement of certain educational milestones, which would affect their ability to pursue higher education or even specialized training for their career. We also see, which is very difficult, loss of scholarships or financial aid. Some AYAs are starting school. It's based on a scholarship or a grant or financial aid, and they can't meet those full-time enrollment requirements or be able to maintain the GPA that they need to stay in the program. We see people losing their scholarships, and this is not their fault.” TS 10:11 “Down the road, you have this stress leading to chronic stress. We know that constant worry about finances can create a chronic stress environment. That is going to impact mental health across the board, which can lead to increased irritability, feelings of sadness, or even conflict among family members. So when we talk about managing these dynamics, we really want to focus on the importance of open communication because a lot of times we see families avoid discussing financial issues to shield each other from that additional stress.” TS 18:06 “One of the challenges that we face with this population is that we might assume that if they're not talking about it, if an AYA is not bringing up finances, that it's not an issue. And so sometimes even our own assumptions or assumptions of healthcare professionals that they don't even need to ask, ‘How are finances going? Are you working currently? Do you feel financially stable? Are you insured?' Often, maybe there's not room for those questions. Maybe the appointments are too rushed. … Healthcare professionals could maybe take a pause to evaluate their own hidden or implicit bias, reflecting on their own experience, really trying to become aware of the assumptions they might have about this population.” TS 32:46
“At the beginning, like when you first meet someone before they've even started anything, kind of get a baseline of ‘What's your ability to complete your daily activities? How is your coordination? How's your speech now? How is your writing ability?' up front before we start anything that could be toxic. And then prior to every treatment, I tend to look at their gait, watch them walk in or walk out of the office, to see if they're changing at all,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about central nervous system toxicity. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CNS toxicities. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy Episode 278: Cancer Symptom Management Basics: Hepatic Complications Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 250: Cancer Symptom Management Basics: Dermatologic Complications Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications ONS Voice articles: Cognitive Impairment Is Much More Than “Chemo Brain” When Delirium Is Recognized and Addressed Early, Patient Outcomes Improve An Oncology Nurse's Guide to Bispecific Antibodies CNS Survivorship Needs More Research, Funding, and Training, Expert Panel Says ONS courses: Essentials in Advanced Practice Symptom Management Treatment and Symptom Management—Oncology RN Nursing Considerations for CAR T-Cell Therapy for Patients With Hematologic Malignancies: Patient Education and Symptom Management ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) Core Curriculum for Oncology Nursing (seventh edition) Clinical Journal of Oncology Nursing articles: Associated Toxicities: Assessment and Management Related to CAR T-Cell Therapy Dronabinol Therapy: Central Nervous System Adverse Events in Adults With Primary Brain Tumors Primary Central Nervous System Lymphoma: Treatment and Nursing Management of Immunocompetent Patients ONS Huddle Card: Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) American Society of Clinical Oncology (ASCO) Nervous System Side Effects Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Biotherapy, immunotherapy, and cellular therapy can cause changes in cognitive function and personality, even without other signs of obvious neurotoxicity. Things like cytokines, whether it's infused or as a result of side effects, can bypass the blood-brain barrier and can also alter that vascular permeability to allow other substances to kind of cross the barrier and can also alter your hypothalamic activity.” TS 2:26 “There's definitely an effect on patients who are older. You know, there's less pliability, less ability of their nervous system to sort of rebound from an insult in some cases. And I think there's more exposure. There's more risk of coexisting conditions, things like diabetes or thyroid issues. There's also higher risk of impaired liver and renal function or dehydration or polypharmacy-type things. So I think there's just a lot of sort of inherent risks as people get older and have more coexisting conditions.” TS 5:33 “[Their caregiver says] they used to read all the time—and if you ask the patients, they're like, “Oh, well, I can't focus on the words because they all seem too blurry.” … But when you, if you ask them specifically, “Is your vision blurry?” they'll say no. Then when you really get down to it, that caregiver piece I think is really crucial in this kind of toxicity, because it's the little things that if you catch them when they're little things, then won't lead to big things.” TS 11:00
“A sense of belonging is what tethers us to those who share in our spaces that work with us. Belonging is fueled by a social connection, which is one of our basic human needs. When you feel safe, supported, and valued, you bring your full, authentic self to work and you're fully engaged to work collaboratively to deliver the best patient care and quite frankly, be the best teammate ever,” Kecia Boyd, DNP, RN, NEA-BC, AOCNS ®, BMTCN®, director of inclusion, diversity, and equity in the department of nursing and patient care services at the Dana-Farber Cancer Institute in Boston, MA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about how nurses can contribute to a community of belonging in their workplace. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), which may be applied to the professional practice and performance ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by December 22, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to inclusion in nursing. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 178: Together, We Can Stop Racism and Create Equity in Nursing ONS Voice articles: Diversity in Nursing: How the Profession Is Addressing Racial and Gender Gaps Diversity in Nursing Begins at the Student Level Achieving Diversity and Inclusion in Nursing Requires a Closer Look at the Profession's Structure Additional ONS resources: DEI Commitment Statement Implicit Bias Huddle Card Introduction to Intentional Conversations Videos Harvard Implicit Association Test The Journal of Excellence in Nursing Leadership article: Equity, diversity, and inclusion: Intersection with quality improvement National Library of Medicine article: Diversity, Equity, and Inclusion in Nursing: The Pathway to Excellence Framework Alignment American Nurses Association (ANA): Promoting Diversity in Nursing and the Role of Leaders To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “For better understanding how belonging is tied into diversity, inclusion, equity, let's put in the context of a party. So, let's say diversity is being invited to that party, equity is receiving the invitation to the party in the way that is right for you, inclusion is being asked to dance when you get to that party, and a sense of belonging is dancing like nobody is watching.” TS 3:43 “A strong sense of belonging is important for nurses because it will help create and sustain a healthy work environment that fosters excellence in patient care and optimal outcomes for us—as staff, as nurses—our patients, and other members of the healthcare team.” TS 4:47 “Building relationships at work is how we build resilience to our everyday work environment. Resilience allows us to overcome those stressful situations and to adapt positively resulting in good wellbeing and mental health.” TS 6:01 “I believe it begins with each of us as individuals to do some self-reflecting or some self-awareness, because a self-reflection will allow us to identify our own unconscious biases, it will allow us to check our assumptions, it will allow us to examine our role of power and privilege, which will lead us to a better understanding about the experiences of historically marginalized groups.” TS 8:38 “It's about changing the culture of a workplace to be more inclusive. And there is a few ways that an organization can do that. And one way is maybe providing a learning and development opportunities in the ID&E space, for example, like this podcast that we're doing now. It allows us to learn about the sense of belonging and also our organizations to offer remote and learning development opportunities in the space. We need organizations to foster a collaborative environment.” TS 11:01 “That's one way you can build a relationship by offering to help, jumping in. And by jumping in, offering to help, and maybe sharing and saying, ‘Oh, I know this happened to me before,' or ‘Sometimes I forget to do that,' it shares your vulnerability, which opens up everybody else to share their vulnerability is really building that trusting relationship. Sharing stories, asking questions, but really connecting with your team. And you do that—you have to talk, and you have to listen.” TS 13:59 “If we cannot care for ourselves and our colleagues, how can we care for others? Right? It's so true that when we're caring for each other, we can care for our patients. And you're right. Patients can see when things are disjointed, when there's not a flow, when there's not a cohesive team. But we're animals, right? So, if as animals, if we're hurt or insulted, we tend to retreat, to go in, we're not going to go out. And so, people see that. When you go in and you're not really sharing and working as a team to deliver this effective and efficient patient care, not part of the whole team, there's a gap, there's a missing. You're not able to add your expertise in the outcome of this patient's care.” TS 20:56 “We talk about words and definition, but how do we make it more actionable? How do you make sense of belonging actionable? And one way that I shared with you is that offer of a chair. It's those small things of being aware of what's around you and looking at what your colleague may need and getting that without asking.” TS 22:10 “We all have unconscious bias. You know, if you have a brain, you're biased. Biases are just due from a lifetime exposure to cultural attitudes, previous experiences, social class, gender, race, just to name a few. But how we can look at that, as we talked about, is that to begin this change, to talk about sense of belonging, it begins with us individually of our own self-awareness of our self-reflecting, and we can do that.” TS 24:03 “We have to learn to be uncomfortable with that, and we don't talk enough about that. Because I believe that growth and comfort can never coexist, because as you're growing, as we're changing, it's uncomfortable. And so, to talk more about that, to be ‘It's okay to be uncomfortable,' and to learn to be comfortable with that because we can't grow without feeling uncomfortable.” TS 27:09
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerThomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline and Pfizer.Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.Faculty/PlannerBeth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
“We incorporate nurses and clinicians and users for any tool from the very beginning. They say, ‘You know, we need help with this.' And then we start ideation: We start understanding the problem, we meet with them, we try to see what is it that they're trying to do, is it feasible given the data we have? We go back, we do some research, feasibility study. We say we think this is something we can predict with decent performance. Now let's do it,” Nasim Eftekhari, MS, executive director of applied artificial intelligence (AI) and data science at the City of Hope National Medical Center in Duarte, CA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about how the use of AI in cancer care affects an oncology nurse's daily work. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 The advertising messages in this episode are brought to you by LUNGevity. Episode Notes Oncology Nursing Podcast: Episode 281: Nursing's Role in AI in Health Care Episode 131: NLM Is Changing Health Care Through the Power of Data ONS Voice articles: New Technology Tools Help Oncology APRNs Improve Patient Outcomes AI Ultrasound Is Nearly 100% Accurate in Detecting Thyroid Cancers Nursing Informaticists Are the Backbone of Technology-Driven Care What ChatGPT Says About Belonging and Oncology Nursing Clinical Journal of Oncology Nursing article: Technology and Humanity Oncology Nursing Forum article: Artificial Intelligence for Oncology Nursing Authors: Potential Utility and Concerns About Large Language Model Chatbots Primers for AI concepts and terminology: Introduction to Artificial Intelligence for Beginners 12 Important Model Evaluation Metrics for Machine Learning Everyone Should Know To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “So, there is a lot of applications of AI in cancer care, so I can't possibly give you an exhaustive list. But the ones that come to my mind, at least the ones that we are actively working on are early detection and diagnosis, treatment planning, predictive modeling for predicting unwanted outcomes, remote monitoring, radiology applications, pathology applications, improving operations and helping the resource allocation, precision medicine, and research. And we also started a year or so incorporating AI and helping with drug discovery.” TS 2:13 “We've been using AI for a very, very long time. Recently, we just hear more about AI, but AI is in our lives, in health care or not, all day, every day. Google Maps, Google search, all of this is enabled by AI, but we may not realize even that we're using it.” TS 8:27 “So, for technical challenges, you have to always consider: Is this model performing in a decent manner for this application? And depending on the use case, that's different. If you're providing a decision support to someone that is impacting patient care, then you have to be very careful about model performance. So, model performance is one technical consideration, then how do you really technically integrate with the EMR system? It's not easy, EMR systems are not usually very open, and that's a whole challenge in itself to be able to read from any EMR system in real time and feed data back into it in real time.” TS 10:16 “For nurses to successfully approach and adopt this work, I think the most important thing is to keep an open mind to really realize that these technologies can, at best, take the mundane part of their work away so they can operate at the top of their license, but what AI does best is to do things that are repetitive and doesn't require a ton of human intelligence. I think that would be very helpful. Just that mindset could make things more collaborative and cooperative, and that's the only way that we can make these successful.” TS 12:37 “What could help is for nurses to learn the basic concepts that are involved in the development and deployment and testing of these models, so that they can really understand the limitations and capabilities and they can take an active part in the development as well. So, it's not like we build something for you and then we're trying to convince you this is good for you. We try to build together. As an AI and computer scientist, I'm always learning the medical language. I try to educate myself about the clinicians' workflows and language, and I think the same needs to happen on the clinician side for us to be able to build tools that really work in their workflows for their everyday life.” TS 13:58 “We incorporate nurses and clinicians and users for any tool that will be developed from the very beginning. So, usually, the need for something, like a predictive model, comes from nurses and doctors. They say, ‘You know, we need help with this.' And then we start ideation: We start understanding the problem, we meet with them, we try to see what is it that they're trying to do, and is it feasible given the data we have? We go back, we do some research, feasibility study. We come back and say we think this is something we can predict, you know, with decent performance. Now let's do it.” TS 14:30 “All of our models, even the ones that have been in production for the longest, we're still getting feedback, we're still improving, and we're still retraining models, not only with new data that becomes available but also with the feedback that we get from our users.” TS 17:43 “For example, after going live, we've had less ICU admissions because of sepsis or septic shock, or after going live had less sepsis mortality, which is very reassuring. So that seems like we're doing the right thing, and our model is working, but if you want to put your scientist hat on, you cannot say 100% this is the impact of the model because there is a lot of different workstreams that are trying to improve those same metrics. And unless you do a clinical trial or what we call in industry A/B testing, where you control for everything else and it's only the model intervention that is the variable, you cannot say for 100% that this is the impact of the model. That's why we combine our qualitative metrics that seem to be right in the right direction with the quantitative metrics.” TS 22:17 “I think for the first time, something has come up that can really make a big change in health care. I could not say this before generative AI. AI has always been helpful, but now I think it's the time to see real change. We're still experimenting. It's really new technology. We are experimenting with in-house development as well as third-party tools that we are testing and evaluating. Again, there's a huge potential in reducing manual labor and documentation, note taking, there are implications in billing and finance, data abstraction for research or whatever other purposes that we need them, tumor boards, predictive modeling, clinical trial matching is one big use case in oncology, and finding similar patients—something that we've been aspiring to for a really long time—seems to be very possible now with these technologies.” TS 25:30 “The users also weigh in. So, if you're considering it to improve clinical operations, the people who will be using the tool will have a say in, ‘Yes, we think this tool will be helpful.' So, it's not just looking at the technical and cybersecurity and ethical and legal aspects, but also is this something that our users will use because that's the ultimate goal. If they don't use it, it doesn't matter how good the tool is. It won't work.” TS 31:13 “Making it successful is not about the technology, but mostly about people and processes and operational support.” TS 33:33 “Helping people, helping clinicians, nurses to be more free of mundane tasks and be able to interact with patients, do patient care, which is what they should be doing, rather than the things that I know a lot of nurses hate. I think we have a very exciting time ahead of us.” TS 38:47
“We really need to do our best to reach people who don't have access to palliative care in their communities, and this is an innovative way for us to do that,” Carey Ramirez, ANP-C, ACHPN, nurse practitioner and manager of advanced practice and supportive care medicine at the City of Hope National Medical Center in Duarte, CA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about how telehealth is overcoming barriers and disparities that previously limited patients' access to timely oncology palliative care. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 NCPD contact hours of nursing continuing professional development (NCPD), which may be applied to the care continuum, coordination of care, nursing practice, oncology nursing practice, psychosocial dimensions of care, quality of life, symptom management, palliative care, supportive care, treatment https://www.oncc.org/ilnaILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by October 20, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to telehealth-based oncology palliative care. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 251: Palliative Care Programs for Patients With Cancer Episode 135: ELNEC Has Trained More Than One Million Nurses in End-of-Life Care Episode 41: Advocating for Palliative Care and Hospice Education ONS Voice articles: Bipartisan PCHETA Legislation Reintroduced in U.S. Senate U.S. Senators Introduce Legislation for Earlier Palliative Care Help Your Patients Prepare for the End From the Beginning APRNs Can Lead by Example When Integrating Palliative Care in Practice Clinical Journal of Oncology Nursing articles: Palliative Care: Oncology Nurses' Confidence in Provision to Patients With Cancer Telehealth in Palliative Care: Communication Strategies From the COVID-19 Pandemic Clinical Oncology Nurse Best Practices: Palliative Care and End-of-Life Conversations Integrating Palliative Care in Hematopoietic Stem Cell Transplantation: A Qualitative Study Exploring Patient, Caregiver, and Clinician Perspectives ONS Palliative Care Huddle Card ONS clinical practice resource: Palliative Care Communication Strategies ONS book: Integration of Palliative Care in Chronic Conditions: An Interdisciplinary Approach Center to Advance Palliative Care (CAPC) Hospice and Palliative Nurses Association (HPNA) National Hospice and Palliative Care Organization (NHPCO) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “If a person is uncertain of their prognosis or if a provider is uncertain of the goals that the patient has for themselves, that might be an appropriate time to consider palliative consultation. These are all important considerations for triggers that might make palliative a possibility for patients in those scenarios. The take-home message, though, is that the sooner that palliative care is involved, the more likely the patient and family are to benefit.” TS 2:51 “From a patient and family perspective, we frequently find that there are misperceptions regarding palliative care. Oftentimes, they'll conflate the word palliative with either hospice or end-of-life care. They unfortunately sometimes believe that they're one and the same. They demonstrate a lack of knowledge regarding the benefits, including the fact that palliative care can and should be provided alongside life-prolonging care.” TS 3:53 “Palliative providers do their best to help patients maintain hope throughout their disease trajectory, regardless of how well or how poorly things are going. I tend to view things in terms of climbing a sand dune: Living with cancer can sometimes feel like you're walking up a sand dune, either at the beach or at the desert, and there will be days where you take two steps forward and you might slide only one step back. There may also be days where you take two steps forward and slide three steps back. And you find, for example, that if you keep trudging toward the top, that because the winds are constantly blowing those dunes, the top you eventually reach might be different than the one you initially set out to reach. And I think that speaks to the changing nature of hope.” TS 6:08 “It's important to ensure that providers are aware of the local services available to them in their respective communities. [And] we often find that from an organizational or a structural barrier perspective, there are lack of access to palliative care in the community. We often find that outpatient programs may not be as robust, or you may find that there is great variation between outpatient programs with regard to quality.” TS 10:10 “We have multiple patient populations who unfortunately do not have equal access to palliative care. They include rural populations, those who come from low socioeconomic backgrounds. We find that male patients and/or patients who are older adults have lower access to palliative care. We find that those who might be either single or live alone, those who might have an immigrant status, those who don't speak English, those who might have certain cancer diagnoses. It may surprise some of you to know that those with hematologic malignancies actually have much lower rates of palliative referral than those with solid tumors.” TS 11:23 “There's a maldistribution of palliative care resources nationwide. We tend to see that many of the resources are in urban areas, and as a result, we find that a great many rural areas are left untouched. I think it's important for us to recognize that these social determinants of health exist. It's important for us to look intentionally at them and whether they affect some of our patient populations and to work together to overcome them.” TS 14:03 “Anecdotally, I've been doing telehealth for about five years and it's been quite well received. It decreases my no-show rates. It improves my ability to monitor patients over time, and it can be carried out safely.” TS 16:12 “It's important to recognize that telehealth can be utilized not only for a planned appointment that might be scheduled to surveil someone every two weeks or every month from a pain and symptom management perspective, it can also be utilized as a same-day possibility. So if, for example, we have a patient who's due to have an MRI tomorrow and their last MRI was stopped in part because they couldn't tolerate it due to pain or symptoms, we might have a primary team reach out to us and ask whether we can see that patient the day prior to their MRI and devise a plan with that patient so that they can tolerate the MRI more easily the next day.” TS 22:26 “Many of our patients no longer have the ability to get to and from their place of worship, and we can sometimes bring their clergy people to them via telehealth video. We also offer psychology services, psychiatry services, child life services, all via telehealth. And I think it's important to recognize that palliative care is actually made up of an interdisciplinary team, including all of the aforementioned specialists who can basically work together to improve the experience of the patient who is living with cancer and being treated for it.” TS 26:41 “Accept the inevitability of ups and downs. Learn from the downs and persevere. The outcomes are definitely worth it.” TS 28:11
“I think the most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes,” Tanya Helms, PA-C, from the division of hematological malignancies and cellular therapy at Duke University Medical Center in Durham, NC, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about what oncology nurses should know about transplantation for patients with non-oncologic conditions such as autoimmune disease, how the transplant process differs for non-oncology indications, and the clinical pearls oncology nurses should consider when caring for patients with autoimmune diseases during the transplantation process. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 NCPD contact hours of nursing continuing professional development (NCPD), which may be applied to the early post-transplant management and education, treatment modalities, diagnosis, staging and treatment planning, or coordination of care ILNA category, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 29, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to hematopoietic stem cell transplantation for scleroderma and other autoimmune diseases. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease Episode 148: Stem Cell Transplant Nursing in the Home Setting ONS Voice article: What Oncology Nurses Need to Know About Vaccination and Cancer (and other immunocompromised diseases) Clinical Journal of Oncology Nursing article: Early Intervention With Transplantation Recipients to Improve Access to and Knowledge of Palliative Care ONS course: Hematopoietic Stem Cell Transplantation ONS Huddle Card™: Hematopoietic Stem Cell Transplantation National Scleroderma Foundation New England Journal of Medicine article about the SCOT trial: Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “The goal of treatment for patients with scleroderma is to reset the immune system, and there are three main components of the regimen used at Duke—that's total body radiation, cyclophosphamide, and ATG. This targets all the areas where the immune effector cells live. We also use CD34 selection, which is a process that separates CD34-positive cells from the stem cell product that's collected prior to transplant, to eliminate the possibility of reinfusing activated immune cells back into the patients.” TS 3:18 “For patients with diffuse scleroderma, you want to offer transplant when they have evidence of significant disease, but they're not so compromised that they can't tolerate or have increased risk of complications from the conditioning regimen. Understanding the patient's rate of disease progression is key when determining to transplant.” TS 6:45 “When a patient is referred, we call the patient, and we talk about how the transplant conditioning regimen works to reset the immune system and stop disease progression. We explain the workup visit and go over an example of the timeline needed to collect the cells, admit to the hospital for conditioning, and the recovery process as an outpatient. We want patients to understand the big picture before they ever come to Duke.” TS 7:57 “Some patients come to us significantly disabled by their scleroderma. They may be in a wheelchair, so they require special vehicles for travel. Patients whose hands are severely involved need assistance with their ADLs [activities of daily living].” TS 11:43 “There have been three clinical trials that show autologous transplant improves event-free survival and overall survival and has been shown to decrease all-cause mortality. But it does not repair damaged gastrointestinal, pulmonary, or cardiac tissue. Any fibrosis that has happened is permanent.” TS 12:22 “The most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes.” TS 13:01 “Social media has been a huge contributor towards patient self-referrals. Patients are telling their stories on Facebook; patients are asking other questions about how to get referred to a transplant center; and patients whose rheumatologists have not referred them will seek out transplant centers to learn more about transplant for scleroderma.” TS 13:48 “For people with hematologic malignancies, it's all about getting that patient to remission and then transplanting them. . . . These patients have experienced chemotherapy and the adverse effects. They know about low blood counts and fatigue and recovery. They know about central lines and transfusions. The scleroderma patients come to transplantation with progressive disease. They've typically not had blood transfusions, but they are now going to receive total body radiation, chemotherapy, and a stem cell transplant over the next six weeks. And it can be overwhelming. . . . Every day is something new for them to process and learn.” TS 14:56 “Patients become pancytopenic, and they are heavily immunosuppressed. They are on steroids during the conditioning regimen to prevent scleroderma flares during conditioning. These patients have a central line so monitoring for infections, such as assessing vital signs for signs and symptoms of infection, and being aware that steroids can mask a fever.” TS 16:49
“I think that as oncology nurses, we need to keep ourselves really educated and up to date with these new therapies, because I honestly feel like we still haven't really seen the long-term effects of this treatment,” ONS member Lisa Parks, MS, APRN-CNP, ANP-BC, nurse practitioner in hepatobiliary surgery at The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center in Columbus, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about recognizing hepatic complications and understanding the basics of its symptom management strategies. This episode is part of a series on cancer symptom management basics; the others are linked below. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 NCPD contact hours of nursing continuing professional development (NCPD), which may be applied to the disease-related biology, treatment, or symptom management, palliative care, supportive care ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 22, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.22, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge in cancer symptom management basics and hepatic complications. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast: Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 250: Cancer Symptom Management Basics: Dermatologic Complications Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications ONS Voice article: To Prevent Hepatotoxicity, Monitor Liver Function During Cancer Treatment Clinical Journal of Oncology Nursing articles: Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Related to Hematopoietic Stem Cell Transplantation Use of Hepatic Artery Infusion Pumps in the Treatment of Hepatic Metastases ONS courses: ONS/ONCC Chemotherapy Immunotherapy Certificate Course ONS/ONCC Radiation Therapy Certificate Course ONS books: Cancer Basics (third edition)https://www.ons.org/books/cancer-basics-third-edition Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) American Gastroenterological Association American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From Today's Episode “There is something called chemotherapy-induced liver injury. What the chemotherapy does is it has a direct hepatotoxic effect on the hepatocytes themselves. If you have preexisting liver disease such as cirrhosis, it can lead to very severe hepatotoxicity because the function of the liver is already compromised by the damage previously done to it.” TS 3:47 “The American Gastroenterological Association published guidelines on the management of HBV reactivation for patients during immunosuppressive treatment, and they basically do recommend any patients with a hep B virus that they receive antiviral prophylaxis to prevent this reactivation from occurring. Also in 2008, the CDC recommended universal HBV screening for all patients before administering chemotherapy. This one you see most commonly in patients who receive chemotherapy for a hematological cancer following hemopoietic stem cell transplantation.” TS 14:19 “One of the most common things that I've encountered in my practice is that there seems to be a thought that once hepatic complications are identified, there is treatment for this, and in these patients, we can't reverse liver injury. Really, what we offer these patients is supportive care. These patients often can decompensate really quickly, and often these patients may require being transferred to the intensive care unit and it's not because there's any intervention that we're going to do. But I think it's very frustrating for nurses to see these severe liver injuries, that are life threatening, and not to be able to do anything about it.” TS 19:06
“I think the take-home message here, though, is to have very specific guidelines at your institution to manage both CRS and ICANS. The protocols should be readily available to all practitioners who may participate in the care of these patients,” ONS member Phyllis McKiernan, MSN, APN, OCN®, advanced practice provider at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS. McKiernan's and Taylor's conversation centered around the nurse's role in recognizing and managing toxicities related to CAR T-cell therapy for hematologic malignancies, specifically ICANS and CRS, which was an educational priority that ONS members identified during two ONS focus groups on the topic in March 2023. McKiernan was one of the content experts for those focus groups. This podcast episode is produced by ONS and supported by funding from Janssen Oncology/Legend Biotech. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. Oncology Nursing Podcast episodes: Oncologic Emergencies 101 series Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment Episode 1: Experiences With CAR T-Cell Therapy ONS Clinical Practice Resources: Chimeric Antigen Receptor T-Cell Therapy: A Timeline of Events and Adverse Events Cytokine Release Syndrome ONS Clinical Update: Focus on Clinical Experiences With CAR T-Cell Therapy ONS course: Nursing Considerations for CAR T-Cell Therapy for Patients With Hematologic Malignancies: Patient Education and Symptom Management ONS Huddle Card™️: Cytokine Release Syndrome ONS Immuno-Oncology Learning Library ONS videos: CAR T-Cell Therapy Cytokine Release Syndrome American Cancer Society American Society for Transplantation and Cellular Therapy Grading Scale for CRS and ICANS Leukemia and Lymphoma Society Multiple Myeloma Research Foundation National Institutes of Health's National Cancer Institute Risk Evaluation and Mitigation Strategies To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “All symptoms need to be investigated fully to determine their cause and thus the best management strategy and not just simply assume that they're related to CAR T.” Timestamp (TS) 9:21 “Accurate grading is really crucial to ensure that the toxicities are identified and managed consistently across the institution.” TS 10:52 “Once the patient shows signs and symptoms of neurotoxicity, they should have a comprehensive neurologic examine, and that should include, a neurology consult, maybe imaging, such as an MRI or CT, and perhaps even a lumbar puncture.” TS 14:12 “Letting patients and their families know what next steps are can alleviate anxiety and give the patients the confidence that the medical team is familiar with these toxicities. And let them know that these toxicities are expected and that there are protocols in place to manage these symptoms.” TS 22:56 “I think that some patients, and even healthcare professionals, who aren't familiar with CAR T believe that the toxicities are always severe and always irreversible. When, in reality, most of the toxicities are mild and managed with minimal intervention or even just supportive care.” TS 23:55 “Early detection, consistent grading, vigilant monitoring, and standardized care plans are crucial to the success of any CAR T program and can also help reduce the risk of the severe adverse effects and hopefully improve outcomes for our patients.” TS 30:26
“The mental and physical health of the healthcare team, especially the nurses, has to come first because if you are not physically and mentally and spiritually in a good place, you cannot help other people. We're going to have less good health care, we are going to have more errors, we're going to have less safety, and we are going to have another 100,000 nurses leaving the field,” Matthew Loscalzo, LCSW, executive director of People and Enterprise Transformation, emeritus professor of supportive care medicine, and professor of population sciences at City of Hope in Duarte, CA, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about the stressors that are affecting nurses. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Music Credit: “Birth of a Hero” by Benjamin Tissot License code: 7B2F6ZBTINETT4WQ Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by June 16, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to supporting the mental health of nurses. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast episodes: Episode 27: How Self-Care Can Impact Your Nursing Practice Episode 85: Nursing Resilience and Self-Care Aren't Optional Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 231: Nurses Thrive in a Healthy Work Culture ONS Voice articles: It's Okay to Put Yourself First Sometimes Leaders Need to Walk the Talk When It Comes to Self-Care, Too Mental Health Teams Build Programs That Prioritize Staff Well-Being Clinical Journal of Oncology Nursing article: Psychosocial Well-Being: An Exploratory Cross-Sectional Evaluation of Loneliness, Anxiety, Depression, Self-Compassion, and Professional Quality of Life in Oncology Nurses ONS Nurse Well-Being Learning Library ONS course: Facilitating Intentional Conversations Addressing Health Worker Burnout: U.S. Surgeon General's Advisory on Building a Thriving Health Workforce U.S. Surgeon General's Framework for Workplace Mental Health and Well-Being U.S. Department of Veterans Affairs: Skills for Psychological Recovery: Field Operations Guide Biopsychosocial Model Learn more about the staff leadership model. To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “There is overwork, but there is something even bigger, even more sinister, and that is this evolving lack of respect throughout our society. But when it manifests in the healthcare system, where people come in vulnerable states to be protected and they have this adversity to those who care most about them, this is a profound change, this is a unique change. Although it is happening in society for all authority, when it's in the healthcare system, it manifests in a profoundly different way, and the impact on nurses cannot be overstated.” Timestamp (TS) 05:44 “There is that space between your brain and your heart that I think we should inhabit. We need to have wisdom, we need to have training, but we also need to go to back to our core values. The core value that other people matter. And mostly, I cannot help those other people until I am centered.” TS 19:35 “Structural change is essential, and structural change only comes with some conflict. And I mean healthy, democratic, respectful conversations with each other, with our teams, to advocate for healthier institutions.” TS 27:18 “I think with all people, but especially in the complex environment of health care, focus on what you can influence. Look at your life as a circle and see yourself in that life and say, ‘What can I actually influence rather than allowing myself to be frustrated by things that I cannot have any control over?'” TS 31:00 “One of the biggest problems is that nurses feel that they should just work harder, cope harder. I get very upset when I hear people say and I see it written that nurses should just practice more meditation. Or they should work harder. That is a misconception. It is toxic, and it is dangerous. We have to look at nurses within in the system, physicians within the system, all the healthcare professionals within the system, and say, ‘How do we get them healthy?' If we don't get them healthy, we don't have a healthy healthcare system. We don't have a healthy society.” TS 36:26
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others
“Just like with anything we do in oncology, a lot of education is required. Nurses and coordinators are critical to start the education and provide effective resources that are reinforced throughout the treatment,” ONS member Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, advanced practice provider at Cleveland Clinic in Ohio, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about how to address knowledge gaps and barriers to practice regarding patients who are preparing for or who have received CAR T-cell therapy for hematologic malignancies. Faiman was one of the content experts for two ONS focus groups on the topic in March 2023. This podcast episode is produced by ONS and supported by funding from Janssen Oncology and Legend Biotech. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. Oncology Nursing Podcast episodes: Episode 1: Experiences With CAR T-Cell Therapy Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes CAR T-Cell Therapy Programs: Essential Elements to Establish a Successful System A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy: Updates in Nursing Management Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings ONS clinical practice resources: Chimeric Antigen Receptor T-Cell Therapy: A Timeline of Events and Adverse Events Cytokine Release Syndrome ONS course: Nursing Considerations for CAR T-Cell Therapy for Patients With Hematologic Malignancies: Patient Education and Symptom Management ONS videos: CAR T-Cell Therapy Cytokine Release Syndrome American Society for Transplantation and Cellular Therapy Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells International Myeloma Foundation Leukemia and Lymphoma Society Multiple Myeloma Research Foundation New England Journal of Medicine article: Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Transplantation and Cellular Therapy article: Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Learn more about CAR T-cell therapy and risk evaluation and mitigation strategies (REMS). To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Just like with anything we do in oncology, there is a lot of education that is required. The same navigators that take care of our patients through the transplant and cellular therapy process, we have similar cellular coordinators that were part of the focus group. These navigators were critical to start the education and provide effective resources that were reinforced throughout the treatment.” Timestamp (TS) 09:00 “The nurses and coordinators play a huge role during the transition of care. Not only do they help with coordinating appointments, but also the scheduling of tests and coordinating with the referring team. I heard a lot in the focus groups about the nurses communicating from inpatient to outpatient, and also coordinating from center to center.” TS 10:22 “Patients can get really nervous when they're feeling sick. I explain it to them like, “You know how you get a flu shot, and you might get a little reaction as we're training your immune system to provide immunity? Well, it's like that, but way worse.' So, you can get really sick feeling and achy from this, and so that psychosocial support is super important.” TS 18:16 “It takes a lot of burden on the patient, caregiver, and the nurse to really be astute to those symptoms and intervene. We do provide wallet cards to patients. We educate the emergency department staff. We also heard about the infection monitoring and caregiver support is absolutely critical. Fortunately, the symptom management has become quite standardized, which really affords the nurses more autonomy to intervene more efficiently.” TS 20:46 “The nurses found for education a teach-back tool to be quite useful. One of the nurses mentioned asking the patient questions such as, ‘What will you do when you have a fever? Tell me what you do,' and “What do you understand from what the doctor just told you?' And so that was just kind of a way that they could go back and forth with the educational process and really understand what the patients understood.” TS 25:46
In this latest episode of ASTCT Talks, Christina Ferraro, MSN, APRN-CNP, BMTCN, is joined by Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, to discuss criteria used to determine who is eligible for CAR T cells, efforts between multi-disciplinary teams to select patients, ethical implications in patient selection and more. About Christina Ferraro Christina Ferraro completed her bachelor of science in nursing at The Ohio State University in 2001 and received a master of science in nursing and certification as a family nurse practitioner from Kent State University in 2016. She joined the Cleveland Clinic in 2003 as a registered nurse on the inpatient blood and marrow transplant unit and became an outpatient BMT nurse coordinator in 2006. Christina has been leading the Victor Fazio, MD BMT Cancer Survivorship Program at the Cleveland Clinic since 2016 and has experience in seeing patients with graft-versus-host disease and patients in long-term follow up, emphasizing patient empowerment, education and support. Christina has presented at numerous regional and national conferences including the Oncology Nursing Conference, Leukemia & Lymphoma Society, BMT Infonet, American Society of Transplantation and Cellular Therapy meetings, and Cleveland Clinic nursing grand rounds. Christina is an active author, presenter and educator on the topic of BMT and survivorship and participates in research focused on survivorship and post-transplant complications. About Beth Faiman Dr. Faiman is an exemplary leader in cancer nursing, conducting innovative research and integrating new medical knowledge into nursing practices. She is a founding member of the International Myeloma Foundation Nurse Leadership Board and co-developed nurse-led consult clinics to expedite diagnosis and management of thrombosis and plasma cell disorders. She is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic. Dr. Faiman has influenced cancer care practice by presenting at international and US national conferences, serving as lecture chair, and receiving numerous awards and accolades. She is a Distinguished Fellow in the American Academy of Nursing and holds an appointment on the American Board of Internal Medicine Hematology maintenance of certification committee. She is editor of the Blood and Marrow Transplant certified Nurse (BMTCN) review manual and editor-in-chief of Journal of the Advanced Practitioner in Oncology (JADPRO).
“The bell can have so much more meaning and significance than just the end of treatment. So, work with your patients to define what the significance of that bell can mean,” ONS member Monica Cfarku, RN, MSN, BMTCN®, CCM, NE-BC, associate vice president and chief of oncology nursing at Duke Cancer Institute in Durham, NC, and member of the North Carolina Triangle ONS Chapter, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS. Cfarku discussed the ethics of the bell that patients with cancer ring following the completion of their treatment and how her institution has redefined the bell's ritual. You can earn free NCPD contact hours by completing the evaluation we've linked in the episode notes. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 28, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to treatment bell meaning and options. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 78: Ethical Distress Impacts Nursing Practice ONS Voice articles: Four R's and Resilience Approach Help Oncology Nurses Respond to Morally Distressing Challenges Redefining the Bell Makes the Ritual Inclusive for All Patients With Cancer Use the Evidence to Integrate Ethics in Teleoncology Care How to Have Ethical Discussions in Your Practice ONS Moral Resilience Huddle Card™ MD Anderson Cancer Center: Ringing the Bell Marks a Milestone in Cancer Treatment Duke Cancer Institute To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “The bell has typically been associated with completion of treatment, and the patient is now considered free of cancer. The challenge with that is when patients that will never get to experience that—because there are certain cancers now that are essentially chronic conditions—they hear that bell and that is not a good sound for them. That can bring a lot of emotions around how they're never going to get to that point.” Timestamp (TS) 02:19 “As nurses, it is our duty to recognize an ethical situation and help to determine what that next action or decision is in those situations. We really need to be applying our ethical sensitivity.” TS 04:06 “The bell doesn't just have to be for the end of treatment. It can be the end of a particular journey, or ringing the bell for courage before you walk in. It can be used for anything.” TS 13:14 “I've seen patients ring the bell before walking into the building. . . . I've been asked to meet patients at the bell on their last day of treatment so they can ring it in celebration. . . . I've seen non-oncology patients that are going into a different part of the campus and their family ring it, and I love to see that, as our bell is being used to inspire hope and courage to so many other patients across Duke University. . . . I've seen staff ring it. . . . This little project has really had a reverberating effect that we did not even anticipate.” TS 16:23 “The bell can have so much more meaning and significance than just the end of treatment. So, work with your patients to define what the significance of that bell can mean.” TS 20:45
“When someone is faced with a cancer diagnosis, you want to really try to work to make that patient an active part of their care team. Understand that there are things out of their control, but there are also things that are within their control. You can teach them how to manage fatigue associated with anemia, or how to prevent falls. These are the things you can do to prevent infection; these are the nutrition things you should focus on to help you feel your best,” ONS member Kimberly Miller, BSN, RN, BMTCN®, transplant case manager at Nebraska Medicine in Omaha, and member of the Metro Omaha ONS Chapter, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about nursing management of cancer-related hematologic complications. This episode is part of a series about cancer symptom management basics. The others are linked in the episode notes. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 21, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to hematologic complications. Episode Notes Complete this evaluation for free NCPD. Previous Oncology Nursing Podcast episodes on cancer symptom management basics Additional Oncology Nursing Podcast episodes: Episode 181: Oncologic Emergencies 101: Febrile Neutropenia Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 220: Oncologic Emergencies 101: Febrile Neutropenia and Sepsis Episode 234: Oncologic Emergencies 101: Thrombotic Thrombocytopenia Purpura ONS book: Cancer Basics (third edition) ONS course: Cancer Basics ONS Symptom Interventions for Prevention of Bleeding American Cancer Society patient education handouts: Low Red Blood Cell Counts (Anemia) Low Platelet Count (Bleeding) Low White Blood Cell Counts (Neutropenia) American Society of Clinical Oncology Answers fact sheets Centers for Disease Control and Prevention patient education on neutropenia Leukemia and Lymphoma Society patient education To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “The biggest complication is infection. You do not have the ability to present with the normal signs and symptoms of infection. You're not going to have redness and swelling and drainage. You're going to have more fever, hypertension, dysuria, shortness of breath, or cough.” Timestamp (TS) 07:22 “Some patients get really nervous if their blood counts get to a certain point. I find that we just try to explain to them, ‘We're watching your labs very frequently, we see you several times a week, these are the complications that can happen,' and talk them through the rationale for not giving a lot of maybe not necessary transfusions.” TS 15:15 “In general, the guidelines are if you expect a patient to have severe prolonged neutropenia, lasting greater than seven days, then you would want to consider giving them an antibiotic to help prevent neutropenic fever. . . . A high-risk patient would benefit from that.” TS 17:23 “Myelosuppression can delay chemotherapy, so patients who are getting treatment for their cancer may experience delays in their next cycle, they may have dose reduction, they may have to discontinue that chemotherapy if they have severe myelosuppression. That could affect their outcomes as far as their cancer treatment goes. Patients who are anemic—if you are fatigued and your legs feel heavy and you feel dizzy when you get up and you fall and your platelets are low as well, that leads to an increased risk of bleeding, and really a decrease in quality of life.” TS 23:30 “Myelosuppresion and cancer treatment in general does carry other toxicities besides the physical: emotional, mental, financial, and social.” TS 25:33 “For a patient with cancer, from diagnosis on, there's a lot that they can't control. When you're faced with that diagnosis, you want to really try to work to make that patient an active part of their care team. So, I think it's important to talk with a patient—understand that there are things out of their control, but there are things that are within their control. You can teach them how to manage fatigue associated with anemia or how to prevent falls. These are the things you can do to prevent infection; these are the nutrition things you should focus on to help you feel your best. Anything that you can let the patient have control over because their life has just changed dramatically.” TS 29:03 “Oncology nurses are wonderful at looking at the patient as a whole person. Keep in mind that there are financial toxicities as well as physical, emotional, and mental. So, it might create a bigger team of people that need to step in and help the patient find the resources that they need to be successful. Also, don't forget about the caregivers.” TS 33:47
It can be easy to get lost in all the different cancer treatments & side effects."What does what again?"Good thing Corissa Decker, BSN, RN, BMTCN is back to teach us about common side effects, mechanisms, & other things to know about chemotherapy & biological therapy, but don't worry: she makes it easy to follow & understand, so you'll walk away with exactly what you need to know!Listen now!Writing your oncology specialty exam case report is a huge undertaking. And it's easy to make silly mistakes that can derail your entire writing process.Make sure you're not forgetting these 5 crucial things when writing your case report!Grab your FREE checklist now! Case reports can seem daunting & overwhelming. And how are you supposed to fit writing into your already busy schedule?You need the Case Report Writing Workshop!Case Report Writing Workshop is my proven method to transform your blank screen into a complete first draft of your case report, without pulling out your hair in the process. Enroll today at TheOncoPT.com/casereport! Case Report Writing Workshop is my proven method to transform your blank screen into a complete first draft of your case report, without pulling out your hair in the process. Best of all, it's approved for 8 PT CEU hours! Enroll today at TheOncoPT.com/casereport.Follow TheOncoPT on Instagram.Follow TheOncoPT on TikTok.Follow TheOncoPT on Twitter.
“A lot of healthcare workers that I talk to say that they are kind of brought up with the culture that violence is part of the job. It's not your job to take abuse,” Chris Snyder, University of Utah Health security manager for the University of Utah Department of Public Safety in Salt Lake City, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS. Snyder gave an overview of violence in health care, educational resources for de-escalation strategies, and violence prevention tips. You can earn free NCPD contact hours after listening to this episode by completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by October 21, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Complete this evaluation for free NCPD. Catch Chris's session at the upcoming 48th Annual ONS Congress® in San Antonio, TX. Centers for Disease Control and Prevention course: Workplace Violence Prevention for Nurses Oncology Nursing Podcast Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice ONS Voice articles: Workforce Violence Requires Legislative Support Protect Yourself and Your Colleagues From the Dark Side of Caring Here's How You Can Confront Workplace Violence in a Healthcare Setting What Do You Stand For? Verbal Abuse Is Still Violence, Joint Commission Says Is Sexual Harassment of Nurses Prevalent in Health Care? ONS Nurse Well-Being Learning Library The Royal Canadian Mounted Police (RCMP) Study: Protocol for a Prospective Investigation of Mental Health Risk and Resilience Factors Occupational Safety and Health Administration Workplace violence definition Occupational Safety and Health Administration data: Workplace Violence in Healthcare: Understanding the Challenge Crisis Prevention Institute To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “If I have a patient who maybe comes in two or three times a month for an appointment, or maybe they're inpatient, I do want to focus on their baseline behavior. Because any deviation from that gives me the opportunity to practice situational awareness and know that something is happening.” Timestamp (TS) 07:36 “The number-one rule is you have to give your undivided attention. All too often we are multitasking and doing different things, and we're in a hurry, or it's the end of our shift, or we're working overtime. But when you just stop and drop everything and give that undivided attention and show that individual that you're there to support them and that you're listening to them and that you're there to help them, it makes a huge difference in setting the path for the rest of their journey.” TS 12:45 “Another reason why we don't see things reported is because a lot of our employees feel like, ‘Hey, it has to be an actual physical act of violence for me to report it. Someone has to actually hit me or grab me or throw something at me.' But workplace violence is defined by the Occupational Safety and Health Administration and other groups as all forms that include verbal aggression, verbal abuse, name calling, intimidation, workplace bullying, sexual harassment, sexual inuendo, in addition to those physical acts of violence.” TS 13:22 “Taking the time to ask questions, explain procedures, even talk about wait times—and in the meantime, tending to a physiological need. . . . Anything like that is a huge step in keeping that person closer to their baseline behavior.” TS 18:50 “We need to trust our intuition because if something doesn't feel right, it most likely isn't right. Sometimes our mind does not connect the dots there, but if the hair on the back of your neck stands up, listen to that.” TS 24:03 “[Another important factor is] training and education. You need some kind of training on de-escalation and it dovetails with personal safety. And the reason I say that is because when we talk about personal safety, we talk a lot about how we communicate, and a big piece of that is nonverbal communication. So, safety, communication, de-escalation, all of those things are important.” TS 29:48 “Know before you go. Have you reviewed a patient's chart? Is there a history? Say we have disruptive behavior—maybe we have a patient who is sexually inappropriate with female staff members. Do all staff members know? Is there a plan in place? . . . Check that patient's chart information. Are there behavioral indicators that we're concerned about or any red flags that we want to be aware of?” TS 31:07 “One major rule of de-escalation is that you cannot control somebody else's behavior. It's not possible. We can only control our own behavior. And by mastering that, we can influence another person's behavior. And hopefully, if they're at the top of that roller coaster, we're not riding up to meet them. We're staying down at the bottom. We want them to come down and meet us because that's when we're going to actually communicate and have a conversation. . . . And also know what our own boundaries are. We're human beings. I could be the best at de-escalation and always maintain my composure, but I have a tipping point as well.” TS 32:42 “Another thing that we don't often discuss is the importance of debriefing. We talk about, ‘Let's debrief as a team,' what went right, what went wrong, what were the triggers, what happened, is everybody okay? That includes physical injury and emotional injury, as well. But we are in the habit of only debriefing bad things. How about we debrief a good thing every once in a while?” TS 37:30
“Oftentimes, local policy changes are the ones that are going to influence your day-to-day practice most directly—and are the ones where your voice has the most power because you're closer to the decision makers. There are so many ways for nurses to become involved in advocacy, and it can be simple things just like voting or being knowledgeable on the issues,” Erica Fischer-Cartlidge, DNP, RN, AOCNS®, EBP-C, chief clinical officer at ONS, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS. Fischer-Cartlidge explained how she discovered advocacy and encouraged oncology nurses to get involved at multiple levels and speak out for their colleagues and patients. You can earn free NCPD contact hours after listening to this episode by completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by October 14, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Complete this evaluation for free NCPD. Get updates on the issues affecting oncology nurses. ONS Center for Advocacy and Health Policy Read more from Alec Stone, MA, MPA, ONS Government Affairs Director. ONS course: Advocacy 101: Making a Difference ONS Voice articles: Nurses Are Pivotal to Advancing Biden's Cancer Moonshot Initiative Legislation and Cancer Care: New Policies Improve Nursing Practice and Patient Outcomes When Healthcare Professionals Join Organizations to Advocate, Patients' Voices Are Heard Climate Change Is Contributing to the Cancer Burden, and Nurses Must Take Action All Politics Is Local, and That's Why You Should Get Involved in ONS Advocacy Clinical Journal of Oncology Nursing articles: Amplifying the Global Impact of Oncology Nursing Advocacy: The Pivotal Role of Oncology Nurses Advocacy and Collaboration: Advancing Cancer Prevention and Screening Voices of Oncology Nursing Society Members Matter in Advocacy and Decisions Related to U.S. Health Policy Resources from the American Nurses Association: Latest Advocacy News Advocacy Toolkit To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “We think of advocacy and policy, and our minds automatically go to the national level in Washington, DC. But advocacy at the local level, even within a local organization or regionally at the state level, are just as important, if not more sometimes. There are so many ways for nurses to become involved, and it can be simple things just like voting or being knowledgeable on the issues. And then even bigger like supporting a candidate or communicating with legislators.” Timestamp (TS) 03:18 “Oftentimes, local policy changes are the ones that are going to influence your day to day most directly. And the ones where your voice has the most power because you're closer to the decision makers. For example, if your hospital was proposing policies around mandatory overtime or floating throughout the hospital, you would really be impacted by those decisions. But chances are, people who are making the decisions are also those you are interacting with on a routine basis. . . . So being involved and sharing your knowledge and experience with decision makers can really influence the outcome.” TS 03:58 “Policy I see as a responsibility to my patients and colleagues now. . . . Politics, which is largely about the process of how things get done, is different from the policy, which is the principles we have to guide what we do. I may not like the process of how something gets done, but that doesn't mean I can turn away from the decisions that are made through the process, because they are going to be the standards that govern my day to day. Whatever side of the aisle you fall on, ultimately, we want to do what's best for the patients and the profession. That's what the policy is all about.” TS 07:05 “Awareness I think is the biggest thing that nurses need. Take time to read what issues are up for discussion and the implications of them, sign up for newsletters related to healthcare advocacy so you're routinely informed, think about what you would want the people who are making the decisions on the issues to know. These are small steps that can really be the foundation.” TS 14:26
“Consider your patient's diagnosis. What kind of cancer do they have? And ask yourself, ‘Could this patient be in disseminated intravascular coagulation (DIC)? Is there something more that we should be doing or looking at?'” Leslie Smith, RN, APRN-CNS, DNP, BMTCN®, AOCNS®, oncology clinical specialist at the National Institutes of Health in Bethesda, MD, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS. Smith discussed the nursing considerations for the management of DIC. This episode is part of a series about oncologic emergencies; the others are linked in the episode notes. You can earn free NCPD contact hours after listening to this episode by completing the evaluation linked below. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by October 7, 2024. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Complete this evaluation for free NCPD. Previous Oncology Nursing Podcast episodes on oncologic emergencies ONS book: Understanding and Managing Oncologic Emergencies: A Resource for Nurses (third edition) ONS courses: Oncologic Emergencies Treatment and Symptom Management—Oncology RN Essentials in Oncologic Emergencies for the Advanced Practice Provider ONS Huddle Cards™ DIC Huddle Card ONS Prevention of Bleeding Symptom Intervention and Guideline UpToDate Information from Cleveland Clinic Information from the National Heart, Lung, and Blood Institute To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “If the D-dimer is high, that is indicative of a clotting issue occurring. So, the next step for the nurse would be to look for the lab or ask for an order—you can order a DIC panel in some institutions—but look at coagulation labs. And really care and support these patients. DIC is not a disease in itself; it is a symptom of a disease, it is a syndrome. And it's indicative of another problem occurring.” Timestamp (TS) 07:09 “In the chronic form, patients who live in a chronic inflammatory state—maybe from arthritis or whatever the process is—their coagulopathy will not be as severe as an acute form. They may have an elevated prothrombin time (PT) or partial thromboplastin time (PTT). Their platelets may be a little bit low and their fibrinogen may be just a little bit low, but it's not life-threatening. And in an acute stage of DIC, it is life-threatening.” TS 08:43 “If we are taking care of patients who have received CAR T cells, for example, nurses know to monitor for cytokine release syndrome, we're watching for fever, we're watching the C-reactive protein levels or the ferritin levels, and we're treating appropriately via tocilizumabs . . . preventing DIC that way. Patients who are at risk for developing sepsis. . . . watching for signs of impeding infection . . . . Those types of things can prevent DIC from occurring.” TS 12:26 “I think it can be a little bit confusing for the nurse because they're vague symptoms. So, if you have a patient that is maybe thrombocytopenic, you could attribute, ‘Well, they have all this petechiae from their thrombocytopenia.' It's difficult. That's why you need to really draw a lab. . . . It is not just one lab or one sign or symptom that will diagnosis DIC. There's no one thing that tells you that the patient has DIC. You need to look at all the lab work to make that determination.” TS 14:15 “Nurses are going to support the patient with transfusions. . . . And this will help in an attempt to normalize the lab or at least get the factors and the platelets back up. And then treating the disease. . . . And then in addition, if the patient is infected or septic, administering the antibiotics.” TS 16:26 “DIC is often thought—especially by patients or family—that once you start that chemotherapy or the antibiotics, that the DIC will go away. That is not true. It can take days to weeks for the DIC to resolve itself. It's not something that is going to happen overnight. The patient will need to continue to be supported.” TS 18:13 “Consider what is the diagnosis of your patient. If they have cancer, what kind of cancer do they have? And ask the question to yourself, ‘Could this patient be in DIC? Is there something more that we should be doing or looking at?'” TS 19:22
What if you could help patients manage their conditions and have complete flexibility in your job? That is exactly what our guest Leslie Parran (MS, RN, BCFWC, LEHP, FMCHC, FDN-P, AOCN, BMTCN, CGP, Essential Oil Coach, Founder and Champion Peacemaker, Peace x Piece Wellness Coaching LLC) did! As a seasoned healthcare professional with a passion for helping chronically ill patients, Leslie developed an interest for holistic healing and functional medicine. Turning her focus from treating chronic illness for preventing it, Leslie founded Peace X Piece Wellness Coaching. By uncovering the hidden causes of ailments, rather than prescribing medications as a bandaid, Leslie helps her patients take an active role in their wellness and comes alongside them to develop their health goals. To learn more about how Leslie is changing lives, visit https://peacexpiecewellnesscoaching.com/ or send her an email directly at leslie@peacexpiecewellnesscoaching.com Don't Miss These Highlights: Leslie's extensive history as a healthcare professional. Experiencing functional medicine firsthand. Difference between functional medicine and western medicine. Customized health coaching tailored to the patient's goals.
A clinical nurse with Pediatric Hematology-Oncology turned into “Super Nurse” in helping a young leukemia patient receive a lifesaving bone marrow transplant
ONS member Elaine DeMeyer, RN, MSN, AOCN®, BMTCN®, founder of beyond Oncology, which creates educational tools and resources for oncology professionals to help change their practice, and member of the Dallas ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how oncology nurses can become entrepreneurs and how you can support your colleagues who are developing niche businesses in the oncology arena. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by December 31, 2023. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. beyond Oncology Healthcare Information and Management Systems Society (HIMSS) article: Nurse Entrepreneurs and How to Make an Innovative Idea Reality Johnson and Johnson information on becoming a nurse entrepreneur Nurse business coaching through NursePreneurs Seminars in Oncology Nursing article: Mentoring the Next Generation of Authors To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Theresa Latchford, RN, MS, AOCNS®, BMTCN®, clinical nurse specialist at Stanford Health Care in Palo Alto, CA, and member of the Silicon Valley ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cytokine release syndrome and its associated immunotherapies. This episode is part of a new series about oncologic emergencies. We'll add a link to future episodes in the show notes after the second episode next month. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by October 8, 2023. Theresa Latchford discloses receiving a speaker honoraria from Kite Gilead and Bristol Myers Squibb. The financial relationship has been mitigated. No other planners or faculty members have anything to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. ONS Voice article: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities ONS Voice article: Learn the Nursing Considerations for Cytokine Release Syndrome ONS Voice article: Nurses Help Patients Weather the Storm of CAR T-Cell Therapy ONS Voice article: Oncology Drug Reference Sheet: Tocilizumab Clinical Journal of Oncology Nursing article: Cytokine-Release Syndrome: Overview and Nursing Implications Clinical Journal of Oncology Nursing STAT sheet on cytokine release syndrome ONS clinical practice resource on cytokine release syndrome ONS course: Essentials in Oncologic Emergencies for the Advanced Practice Provider ONS video: Cytokine Release Syndrome BMT Infonet Leukemia and Lymphoma Society 2021 study on cytokine release syndrome and associated neurotoxicity in cancer immunotherapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Ellen Olson, RN, MS, CPNP, BMTCN®, CPHON®, bone marrow transplant pediatric nurse practitioner at Children's Healthcare of Atlanta Aflac Cancer and the Blood Disorder Service in Emory University's Department of Pediatrics, both in Georgia, and member of the Metro Atlanta ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss stem cell transplantation as a treatment option for pediatric sickle cell disease. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 17, 2023. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Complete this evaluation for free NCPD. Additional Oncology Nursing Podcast episodes on pediatric patients with cancer Additional Oncology Nursing Podcast episodes on transplantation ONS Voice article: FDA Approves L-Glutamine Powder for the Treatment of Sickle Cell Disease ONS Voice article: Tips for Managing Chronic Pain in High-Risk Patient Populations Clinical Journal of Oncology Nursing article: Young Adults With Sickle Cell Disease: Challenges With Transition to Adult Health Care Be the Match information on sickle cell disease Centers for Disease Control and Prevention information on sickle cell disease National Institutes of Health guidelines on sickle cell disease Sickle Cell Disease Association of America 2010 study by Walters et al. on transplants for sickle cell disease To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Naomi Cazeau, RN, MSN, ANP-BC, AOCNP®, nurse practitioner at Memorial Sloan Kettering Cancer Center's outpatient bone marrow transplant unit in New York City and member of the New York City ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss haploidentical stem cell transplants to increase donor options for Black, Indigenous, and people of color (BIPOC). Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 27, 2023. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 59: Blood and Marrow Transplant Nursing Oncology Nursing Podcast Episode 148: Stem Cell Transplant Nursing in the Home Setting Oncology Nursing Podcast Episode 163: HLA Testing and More for Hematopoietic Stem Cell Transplant Donor Selection ONS Voice article: The Case of the Cord Blood Match ONS STAT Sheet: Cytokine Release Syndrome ONS book: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) BMTCN® certification American Society for Transplantation and Cellular Therapy National Marrow Donor Program U.S. Health Resources and Services Administration information on transplants 2019 meta-analysis of post-transplant cyclophosphamide therapy 2019 study of racial disparities in access to HLA-matched, unrelated donor transplants 2019 trial comparing Black and White patients following post-transplant cyclophosphamide-based haploidentical transplant 2020 study of cord blood versus haploidentical transplant in Black patients To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Joanne Kelly, RN, BSN, OCN®, blood and marrow transplant coordinator at SSM Health Saint Louis University Hospital in Missouri and member of the St. Louis ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss what oncology nurses need to know about hematopoietic stem cell transplant donor selection and testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by July 9, 2023. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 59: Blood and Marrow Transplant Nursing ONS Voice article: The Case of the Cord Blood Match ONS Voice article: The Evolving Landscape of Cell Transplant Therapy in Cancer Care ONS Voice article: Patients Struggle to Access BMT During COVID-19 OCN® Certification Review Bundle ONS book: BMTCN® Certification Review Manual ONS book: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nursing Certification Corporation information on BMTCN® certification Oncology Nursing Foundation's Josh Gottheil Bone Marrow Transplant Career Development Award Be the Match Foundation for the Accreditation of Cellular Therapy Leukemia and Lymphoma Society To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Seth Eisenberg, RN, ASN, OCN®, BMTCN®, professional practice coordinator of infusion services at Seattle Cancer Care Alliance in Washington and member of the Puget Sound ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how to safely administer bevacizumab. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by June 25, 2023. Seth Eisenberg disclosed receiving a speaker honorarium from Genentech Inc. The financial relationship has been mitigated. No other planners or faculty members have anything to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Previous Oncology Nursing Podcast episodes on outpatient oncology drug infusion ONS Voice article: FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer ONS Voice article: FDA Approves First Biosimilar for Cancer Treatment ONS Voice article: FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers ONS Voice article: The Names of Targeted Therapies Give Clues to How They Work ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice ONS Communities thread on port placement ONS Communities thread on vital signs Manufacturers' healthcare provider pages for bevacizumab and the two biosimilars currently approved at the time of this episode (bevacizumab-awwb and bevacizumab-bvzr) National Institute for Occupational Safety and Health list of hazardous drugs To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
ONS member Seth Eisenberg, RN, ASN, OCN®, BMTCN®, professional practice coordinator of infusion services at Seattle Cancer Care Alliance in Washington and member of the Puget Sound ONS Chapter, joins Stephanie Jardine, oncology clinical specialist at ONS, to discuss how to safely administer rituximab. This episode is part of an ongoing series about outpatient oncology drug infusion; the others are linked in the episode notes. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 23, 2023. The planners and faculty for this episode have no conflicts to disclose, and the episode has no commercial support. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Previous Oncology Nursing Podcast episodes on outpatient oncology drug infusion ONS Voice article: Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab ONS Voice article: What Oncology Nurses Need to Know About Subcutaneous Rituxan Hycela ONS Voice article: The Names of Targeted Therapies Give Clues to How They Work ONS Voice article: What Oncology Nurses Need to Know About Tumor Lysis Syndrome ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice ONS Communities thread on double check and hazardous drugs ONS Communities thread on rituximab spills Infusion Nurses Society (INS)
ONS member Martha Lassiter, MSN, RN, BMTCN, AOCNS®, clinical nurse specialist of adult bone marrow transplant and hematologic malignancies at Duke University Medical Center in Durham, NC, and member of the North Carolina Triangle ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss the home-based transplant program Duke offers as part of an ongoing clinical trial. The advertising messages in this episode are supported by the American College of Surgeons Cancer Programs. Episode Notes Check out these resources from today's episode: NCPD contact hours are not available for this episode. Oncology Nursing Podcast Episode 53: Home Care Nursing for Patients With Cancer Oncology Nursing Podcast Episode 59: Blood and Marrow Transplant Nursing ONS Voice article: No Place Like It: Home Care for Patients With Cancer ONS book: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Report of a preliminary analysis of Duke's home-based transplant program Karolinska University Hospital's first article on home-based transplant care Karolinska University Hospital's latest article on home-based transplant care
ONS member Cecily Snyder, BSN, RN, OCN®, BMTCN®, transplant case manager of the blood and marrow transplantation program at Nebraska Medicine in Omaha and member of the Metro Omaha ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss T-cell therapy and how it's changed approaches to cancer treatment and patient management for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by January 22, 2022. The planners and faculty for this episode have no conflicts to disclose, and the episode has no commercial support. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Episode Notes Check out these resources from today's episode: Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 1: Experiences With CAR T-Cell Therapy ONS Voice article: Nurses Help Patients Weather the Storm of CAR T-Cell Therapy ONS Voice article: The Evolving Landscape of Cell Transplant Therapy in Cancer Care Clinical Journal of Oncology Nursing supplement on CAR T-cell therapy ONS course: Immuno-Oncology for the Oncology Nurse Case Study—CAR T-Cell Therapy American Cancer Society's information on types of stem cell and bone marrow transplants American Society for Transplantation and Cellular Therapy Center for International Blood and Marrow Transplant Research Clinicaltrials.gov studies on CAR T-cell therapy Leukemia and Lymphoma Society resources on CAR T-cell therapy National Marrow Donor Program
ONS member Seth Eisenberg, RN, ADN, OCN®, BMTCN®, professional practice coordinator of infusion services at Seattle Cancer Care Alliance in Washington and member of the Puget Sound ONS Chapter, joins Chris Pirschel, ONS staff writer/producer, to discuss the important aspects of safe handling in oncology nursing, what the upcoming USP chapter launch will mean for practice, and how healthcare professionals can advocate for safety in their institutions. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 Episode Notes: Check out these resources from today's episode: Complete this evaluation for free nursing continuing professional development. Handle With Care: How USP Will Affect Nursing Practice What Oncology Nurses Need to Know About USP Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Episode 68: Empowering Healthcare Workers to Handle Hazardous Drugs Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology Hazardous Drug Exposures in Health Care Hematology/Oncology Pharmacy Association USP General Chapter Hazardous Drugs—Handling in Healthcare Settings
ONS member Kim Miller, RN, BSN, BMTCN®, transplant case manager at Nebraska Medicine in Omaha, joins Chris Pirschel, ONS staff writer, to discuss patients receiving blood and marrow transplants (BMT), the complexities of working with the BMT population, and the role of nurses play in BMT patient care. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 Episode Notes: Check out these resources from today's episode: Complete this evaluation for free nursing continuing professional development. Episode 27: How Self-Care Can Impact Your Nursing Practice Blood & Marrow Transplant – ONS Communities What Is the Role of Interprofessional Teams in a BMT Unit? Blood and Marrow Transplant Certified Nurse - ONCC BMTCN® Certification Review Manual Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice
ONS members Lenise Taylor, MN, RN, AOCNS®, BMTCN®, clinical nurse specialist (CNS) at Seattle Cancer Care Alliance, and Nancy Froggatt, MN, RN, CNL, clinical nurse leader (CNL) at Froedert Hospital in Milwaukee, WI, join Chris Pirschel, ONS staff writer, to discuss the differences between CNS and CNL roles, how they affect practice, and what nurses considering either role need to know. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/by/3.0 Episode Notes: Check out these resources from today's episode: Complete this evaluation for free nursing continuing professional development. CNS or CNL: Which One Is Right for Me? National Association of Clinical Nurse Specialists Clinical Nurse Leader Association American Association of Colleges of Nursing Clinical Nurse Leader resource page National CNS Standards and Guidelines
ONS member Christine Magnus Moore, RN, BSN, PHN, BMTCN®, author, cancer survivor, public speaker, and stem cell transplant nurse coordinator at the City of Hope, joins ONS's Chris Pirschel to discuss cancer survivorship, how nurses can care for patients with chronic diseases, and more. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License http://creativecommons.org/licenses/by/3.0 Episode Notes: Check out these resources from today's episode: Survivorship Care Standards for Accreditation Creating and Sustaining Survivorship Care Plans in Practice Survivorship Articles at the Clinical Journal of Oncology Nursing Scars of Survivorship Journey Forward Christine Magnus Moore Both Sides of the Bedside: From Oncology Nurse to Patient, an RN's Journey with Cancer
© 2020-2025 Ivy Podcast Discovery LLC
